uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.1435 | Q17 | What gene does the drug Estramustine Phosphate Sodium target? | The drug Estramustine Phosphate Sodium targets the gene ESR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%estramustine phosphate sodium%" OR LOWER(tradeNames_string) LIKE "%estramustine phosphate sodium%" OR LOWER(drugSynonyms_string) LIKE "%estramustine phosphate sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5377', 'drugName': 'Estramustine Phosphate Sodium', 'tradeNames_string': 'Emcyt', 'drugSynonyms_string': 'Estramustine 17-(dihydrogenphosphate) disodium salt anhydrous, Estramustine 17-(dihydrogenphosphate) disodium salt monohydrate, Estramustine phosphate sodium, Estramustine phosphate sodium hydrate, Estramustine phosphate sodium monohydrate, Estramustine sodium phosphate, RO 21-8837/001, RO-218837-001', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Kidney Cancer (MONDO_0002367), Lymphoma (EFO_0000574), Carcinoma (EFO_0000313), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1007 | Q17 | What gene does the drug Azd-6482 target? | The drug Azd-6482 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 8 genes: PIK3CB, PIK3R3, PIK3R5, PIK3CG, PIK3R2, PIK3R1, PIK3CA and PIK3CD | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azd-6482%" OR LOWER(tradeNames_string) LIKE "%azd-6482%" OR LOWER(drugSynonyms_string) LIKE "%azd-6482%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_233', 'drugName': 'Azd-6482', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD-6482, AZD6482, Azd 6482, Azd-6482', 'linkedDiseasesDrug_string': 'Ischemic Stroke (HP_0002140)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'numberLinkedTargets': 8}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.894 | Q17 | What gene does the drug Fenofibrate target? | The drug Fenofibrate targets the gene PPARA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fenofibrate%" OR LOWER(tradeNames_string) LIKE "%fenofibrate%" OR LOWER(drugSynonyms_string) LIKE "%fenofibrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1497', 'drugName': 'Fenofibrate', 'tradeNames_string': 'Antara, Antara (micronized), Fenofibrate, Fenofibrate (micronized), Fenogal, Fenoglide, Lipantil, Lipantil micro 200, Lipantil micro 267, Lipantil micro 67, Lipidil, Lipofen, Supralip 160, Tricor, Tricor (micronized), Triglide', 'drugSynonyms_string': 'Fenofibrate, Fenofibrate delayed release, Fenofibrate micronized, NSC-281319', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Coronary Artery Disease (EFO_0001645), Multiple Myeloma (EFO_0001378), Combined Hyperlipidemia (Orphanet_79211), Obesity (EFO_0001073), Hypothyroidism (EFO_0004705), Metabolic Disease (EFO_0000589), Primary Biliary Cirrhosis (EFO_1001486), Diabetic Retinopathy (EFO_0003770), Huntington Disease (MONDO_0007739), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Non-Alcoholic Steatohepatitis (EFO_1001249), Disorder Of Lipid Metabolism (Orphanet_309005), Abnormal Circulating Lipid Concentration (HP_0003119), Hypercholesterolemia (HP_0003124), Hiv-1 Infection (EFO_0000180), Hyperlipoproteinemia (MONDO_0037748), Alcohol Dependence (MONDO_0007079), Hyperlipoproteinemia Type 3 (MONDO_0018473), Lipodystrophy (EFO_1000727), Diabetic Nephropathy (EFO_0000401), Burn (EFO_0009516), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914), Sclerosing Cholangitis (EFO_0004268)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_347', 'drugName': 'Fenofibric Acid', 'tradeNames_string': 'Fenocor-67, Fenogal, Fibricor, Lipanthyl, Lipofen, Lofibra, Supralip, Trilipix', 'drugSynonyms_string': 'Fenofibrate free acid, Fenofibrate related compound b, Fenofibric acid, LF-153, NSC-281318, Procetofenic acid', 'linkedDiseasesDrug_string': 'Hypertriglyceridemia (EFO_0004211), Coronary Artery Disease (EFO_0001645), Medulloblastoma (EFO_0002939), Combined Hyperlipidemia (Orphanet_79211), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Cholestasis (MONDO_0001751), Disorder Of Lipid Metabolism (Orphanet_309005), Type 2 Diabetes Mellitus (MONDO_0005148), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4196', 'drugName': 'Choline Fenofibrate', 'tradeNames_string': 'Trilipix', 'drugSynonyms_string': 'ABT-335, Choline fenofibrate, Fenofibric acid choline salt', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Combined Hyperlipidemia (Orphanet_79211), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Disorder Of Lipid Metabolism (Orphanet_309005)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1495 | Q17 | What gene does the drug Heparin Calcium target? | The drug Heparin Calcium targets the gene SERPINC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%heparin calcium%" OR LOWER(tradeNames_string) LIKE "%heparin calcium%" OR LOWER(drugSynonyms_string) LIKE "%heparin calcium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_843', 'drugName': 'Heparin Calcium', 'tradeNames_string': 'Calciparine, Uniparin ca', 'drugSynonyms_string': 'Ecasolv, Heparin calcium, Heparin calcium salt, Heparinum calcicum', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Henoch-Schoenlein Purpura (EFO_1000965), Eye Disease (EFO_0003966), Habitual Abortion (EFO_1000954), Varicose Veins (HP_0002619)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SERPINC1 (ENSG00000117601)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.335 | Q17 | What gene does the drug Tegaserod target? | The drug Tegaserod targets the gene HTR4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tegaserod%" OR LOWER(tradeNames_string) LIKE "%tegaserod%" OR LOWER(drugSynonyms_string) LIKE "%tegaserod%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4231', 'drugName': 'Tegaserod', 'tradeNames_string': 'Zelmac', 'drugSynonyms_string': 'HTF 919, SDZ-HTF-919, Tegaserod', 'linkedDiseasesDrug_string': 'Dyspepsia (EFO_0008533), Constipation (HP_0002019), Constipation Disorder (MONDO_0002203), Irritable Bowel Syndrome (EFO_0000555), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2042', 'drugName': 'Tegaserod Maleate', 'tradeNames_string': 'Zelmac, Zelnorm', 'drugSynonyms_string': 'HTF 919, HTF-919, NSC-760425, Tegaserod maleate', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555), Constipation Disorder (MONDO_0002203)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.975 | Q17 | What gene does the drug Tariquidar target? | The drug Tariquidar is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ABCB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tariquidar%" OR LOWER(tradeNames_string) LIKE "%tariquidar%" OR LOWER(drugSynonyms_string) LIKE "%tariquidar%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3894', 'drugName': 'Tariquidar', 'tradeNames_string': '', 'drugSynonyms_string': 'Tariquidar, XR-9576, XR9576', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Neuropathic Pain (EFO_0005762), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ABCB1 (ENSG00000085563)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.197 | Q17 | What gene does the drug Tipiracil Hydrochloride target? | The drug Tipiracil Hydrochloride targets the gene TYMP. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tipiracil hydrochloride%" OR LOWER(tradeNames_string) LIKE "%tipiracil hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%tipiracil hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4740', 'drugName': 'Tipiracil Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'TAS-1-462, TPI, Tipiracil hydrochloride', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Rectal Carcinoma (MONDO_0044937), Colorectal Adenocarcinoma (EFO_0000365)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TYMP (ENSG00000025708)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.520 | Q17 | What gene does the drug Lapatinib target? | The drug Lapatinib targets 2 genes: ERBB2 and EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lapatinib%" OR LOWER(tradeNames_string) LIKE "%lapatinib%" OR LOWER(drugSynonyms_string) LIKE "%lapatinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2161', 'drugName': 'Lapatinib Ditosylate', 'tradeNames_string': 'Tykerb', 'drugSynonyms_string': 'GW-572016F, GW572016F, Lapatinib, Lapatinib ditoluenesulfonate monohydrate, Lapatinib ditosylate, Lapatinib ditosylate anhydrous, Lapatinib ditosylate monohydrate, Lapatinib tosilate, Lapatinib tosilate hydrate, Tycerb', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Gliosarcoma (EFO_1001465), Pancreatic Carcinoma (EFO_0002618), Head And Neck Malignant Neoplasia (EFO_0006859), Prostate Cancer (MONDO_0008315), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Neoplasm (EFO_0000616), Breast Cancer (MONDO_0007254), Urinary Bladder Cancer (MONDO_0001187), Thyroid Carcinoma (EFO_0002892), Breast Neoplasm (EFO_0003869), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Oropharyngeal Carcinoma (MONDO_0044926), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Endometrial Carcinoma (EFO_1001512), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2160', 'drugName': 'Lapatinib Ditosylate', 'tradeNames_string': 'Tykerb', 'drugSynonyms_string': 'GW-572016F, GW572016F, Lapatinib, Lapatinib ditoluenesulfonate monohydrate, Lapatinib ditosylate, Lapatinib ditosylate anhydrous, Lapatinib ditosylate monohydrate, Lapatinib tosilate, Lapatinib tosilate hydrate, Tycerb', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Gliosarcoma (EFO_1001465), Pancreatic Carcinoma (EFO_0002618), Head And Neck Malignant Neoplasia (EFO_0006859), Prostate Cancer (MONDO_0008315), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Neoplasm (EFO_0000616), Breast Cancer (MONDO_0007254), Urinary Bladder Cancer (MONDO_0001187), Thyroid Carcinoma (EFO_0002892), Breast Neoplasm (EFO_0003869), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Oropharyngeal Carcinoma (MONDO_0044926), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Endometrial Carcinoma (EFO_1001512), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1363', 'drugName': 'Lapatinib', 'tradeNames_string': 'Tyverb', 'drugSynonyms_string': 'GSK-572016, GW-2016, GW-572016, GW-572016X, GW572016, Lapatinib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Pituitary Gland Adenoma (EFO_1000478), Thyroid Carcinoma (EFO_0002892), Breast Ductal Adenocarcinoma (EFO_0006318), Colorectal Carcinoma (EFO_1001951), Endometrial Cancer (MONDO_0011962), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Brain Disease (EFO_0005774), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Endometrial Carcinoma (EFO_1001512), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Urinary Bladder Carcinoma (MONDO_0004986), Hypopharyngeal Carcinoma (EFO_0002938), Head And Neck Neoplasia (EFO_0005950), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Oropharyngeal Carcinoma (MONDO_0044926), Cervical Cancer (MONDO_0002974), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Chronic Kidney Disease (EFO_0003884), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1362', 'drugName': 'Lapatinib', 'tradeNames_string': 'Tyverb', 'drugSynonyms_string': 'GSK-572016, GW-2016, GW-572016, GW-572016X, GW572016, Lapatinib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Pituitary Gland Adenoma (EFO_1000478), Thyroid Carcinoma (EFO_0002892), Breast Ductal Adenocarcinoma (EFO_0006318), Colorectal Carcinoma (EFO_1001951), Endometrial Cancer (MONDO_0011962), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Brain Disease (EFO_0005774), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Endometrial Carcinoma (EFO_1001512), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Urinary Bladder Carcinoma (MONDO_0004986), Hypopharyngeal Carcinoma (EFO_0002938), Head And Neck Neoplasia (EFO_0005950), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Oropharyngeal Carcinoma (MONDO_0044926), Cervical Cancer (MONDO_0002974), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Chronic Kidney Disease (EFO_0003884), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.459 | Q17 | What gene does the drug Gz-389988 target? | The drug Gz-389988 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene NTRK1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gz-389988%" OR LOWER(tradeNames_string) LIKE "%gz-389988%" OR LOWER(drugSynonyms_string) LIKE "%gz-389988%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4929', 'drugName': 'Gz-389988', 'tradeNames_string': '', 'drugSynonyms_string': 'GZ-389988, GZ389988, Gz-389988, Gz389988', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'NTRK1 (ENSG00000198400)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1714 | Q17 | What gene does the drug Tolmetin Sodium target? | The drug Tolmetin Sodium targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tolmetin sodium%" OR LOWER(tradeNames_string) LIKE "%tolmetin sodium%" OR LOWER(drugSynonyms_string) LIKE "%tolmetin sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1392', 'drugName': 'Tolmetin Sodium', 'tradeNames_string': 'Tolectin, Tolectin 600, Tolectin ds, Tolmetin sodium', 'drugSynonyms_string': 'MCN-2559-21-98, NSC-757341, Sodium tolmetin, Tolmetin sodium, Tolmetin sodium anhydrous, Tolmetin sodium dihydrate, Tolmetin sodium salt dihydrate', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.326 | Q17 | What gene does the drug Oxybate target? | The drug Oxybate targets 2 genes: GABBR2 and GABBR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxybate%" OR LOWER(tradeNames_string) LIKE "%oxybate%" OR LOWER(drugSynonyms_string) LIKE "%oxybate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2097', 'drugName': 'Calcium Oxybate', 'tradeNames_string': '', 'drugSynonyms_string': 'Calcium oxybate, Oxybate calcium', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4208', 'drugName': 'Sodium Oxybate', 'tradeNames_string': 'Xyrem', 'drugSynonyms_string': '.gamma.-hydroxybutyrate sodium salt, Catabate, Lumryz, NSC-84223, Oxybate sodium, Sodium oxybat, Sodium oxybate, Sodium oxybutyrate, WY-3478', 'linkedDiseasesDrug_string': 'Idiopathic Hypersomnia (MONDO_0018044), Sleep Disorder (EFO_0008568), Essential Tremor (EFO_0003108), Pain (EFO_0003843), Alternating Hemiplegia Of Childhood (MONDO_0016241), Spasmodic Dystonia (MONDO_0000485), Parkinson Disease (MONDO_0005180), Narcolepsy (MONDO_0021107), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Fibromyalgia (EFO_0005687), Eating Disorder (EFO_0005203), Tremor (HP_0001337)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4894', 'drugName': 'Oxybate', 'tradeNames_string': '', 'drugSynonyms_string': '.gamma.-hydroxybutyrate, Gamma hydroxybutyrate, Gamma-hydroxybutyrate, Oxybate, Xyrem', 'linkedDiseasesDrug_string': 'Idiopathic Hypersomnia (MONDO_0018044), Sleep Disorder (EFO_0008568), Essential Tremor (EFO_0003108), Alternating Hemiplegia Of Childhood (MONDO_0016241), Pain (EFO_0003843), Spasmodic Dystonia (MONDO_0000485), Narcolepsy (MONDO_0021107), Parkinson Disease (MONDO_0005180), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Fibromyalgia (EFO_0005687), Eating Disorder (EFO_0005203), Tremor (HP_0001337)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2573', 'drugName': 'Potassium Oxybate', 'tradeNames_string': '', 'drugSynonyms_string': 'Oxybate potassium, Potassium oxybate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2016', 'drugName': 'Magnesium Oxybate', 'tradeNames_string': '', 'drugSynonyms_string': 'Magnesium oxybate, Oxybate magnesium', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1323 | Q17 | What gene does the drug Sch-900776 target? | The drug Sch-900776 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CHEK1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sch-900776%" OR LOWER(tradeNames_string) LIKE "%sch-900776%" OR LOWER(drugSynonyms_string) LIKE "%sch-900776%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3221', 'drugName': 'Sch-900776', 'tradeNames_string': '', 'drugSynonyms_string': 'MK-8776, Mk-8776, SCH 900776, SCH-900776, Sch-900776', 'linkedDiseasesDrug_string': 'Non-Hodgkins Lymphoma (EFO_0005952), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Chronic Myelogenous Leukemia (EFO_0000339), Hodgkins Lymphoma (EFO_0000183)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHEK1 (ENSG00000149554)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.269 | Q17 | What gene does the drug Lovastatin target? | The drug Lovastatin targets the gene HMGCR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lovastatin%" OR LOWER(tradeNames_string) LIKE "%lovastatin%" OR LOWER(drugSynonyms_string) LIKE "%lovastatin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4581', 'drugName': 'Lovastatin', 'tradeNames_string': 'Altoprev, Lovastatin, Mevacor, Mevinacor, Mevinacor 10, Mevinacor 40', 'drugSynonyms_string': '6.alpha.-methylcompactin, C10AA02, L-154803, Lovastatin, MK-803, Mevinolin, Mevlor, Monacolin k, NSC-758662, Simvastatin impurity, lovastatin-, Sivlor', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Cerebral Arteriovenous Malformation (Orphanet_46724), Hypothyroidism (EFO_0004705), Metabolic Disease (EFO_0000589), Ovarian Cancer (MONDO_0008170), Myocardial Ischemia (EFO_1001375), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Coronary Atherosclerosis (MONDO_0021661), Fragile X Syndrome (MONDO_0010383), Cerebrotendinous Xanthomatosis (MONDO_0008948), Cardiovascular Disease (EFO_0000319), Parkinson Disease (MONDO_0005180), Acute Myeloid Leukemia (EFO_0000222), Disorder Of Lipid Metabolism (Orphanet_309005), Asthma (MONDO_0004979), Neurofibromatosis Type 1 (MONDO_0018975), Stroke (EFO_0000712), Chronic Obstructive Pulmonary Disease (EFO_0000341), Hypercholesterolemia (HP_0003124), Porokeratosis (EFO_1000757), Learning Disability (MONDO_0004681), Inflammation (MP_0001845), Rett Syndrome (MONDO_0010726), Rheumatoid Arthritis (EFO_0000685), Heart Disease (EFO_0003777), Hiv Infection (EFO_0000764), Cognitive Impairment (HP_0100543), Intermittent Vascular Claudication (EFO_0003876), Internal Carotid Artery Stenosis (EFO_0002615), Cerebral Atherosclerosis (EFO_1000860), Melanoma (EFO_0000756), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.799 | Q17 | What gene does the drug Estradiol Acetate target? | The drug Estradiol Acetate targets the gene ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%estradiol acetate%" OR LOWER(tradeNames_string) LIKE "%estradiol acetate%" OR LOWER(drugSynonyms_string) LIKE "%estradiol acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3260', 'drugName': 'Estradiol Acetate', 'tradeNames_string': 'Femring, Femtrace', 'drugSynonyms_string': 'E3A, ESTRADIOL-3-ACETATE, Estradiol 3-acetate, Estradiol acetate', 'linkedDiseasesDrug_string': 'Atrophy (EFO_1000096), Menopause (EFO_0003922)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1432 | Q17 | What gene does the drug Alpidem target? | The drug Alpidem targets the gene TSPO. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alpidem%" OR LOWER(tradeNames_string) LIKE "%alpidem%" OR LOWER(drugSynonyms_string) LIKE "%alpidem%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4038', 'drugName': 'Alpidem', 'tradeNames_string': '', 'drugSynonyms_string': 'Alpidem, SL 80.0342-00, SL-80.0342-00', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TSPO (ENSG00000100300)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.70 | Q17 | What gene does the drug Ibandronate Sodium target? | The drug Ibandronate Sodium targets the gene FDPS. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ibandronate sodium%" OR LOWER(tradeNames_string) LIKE "%ibandronate sodium%" OR LOWER(drugSynonyms_string) LIKE "%ibandronate sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2230', 'drugName': 'Ibandronate Sodium', 'tradeNames_string': 'Boniva, Ibandronate sodium', 'drugSynonyms_string': 'BM 21.0955 NA H20, BM-21.0955, BM-210955, Ibandronate monosodium monohydrate, Ibandronate sodium, Ibandronate sodium hydrate, Ibandronate sodium monohydrate, Ibandronic acid sodium salt, Ibandronic acid sodium salt monohydrate, Ibandronic sodium monohydrate, NSC-759815', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Osteopenia (HP_0000938), Postmenopausal Osteoporosis (EFO_0003854), Breast Cancer (MONDO_0007254), Pain (EFO_0003843)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FDPS (ENSG00000160752)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.938 | Q17 | What gene does the drug Amiodarone Hydrochloride target? | The drug Amiodarone Hydrochloride targets the gene KCNH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amiodarone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%amiodarone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%amiodarone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3146', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_string': 'Amidox, Amiodarone hydrochloride, Amyben, Cordarone, Cordarone x, Cordarone x 100, Cordarone x 200, Darmil, Nexterone, Pacerone', 'drugSynonyms_string': 'Amiodar, Amiodarone, Amiodarone hcl, Amiodarone hydrochloride, L-3428, Miodaron, NSC-343341, NSC-85442, Ortacrone, Ritmocardyl, SK&F-33134-A, SKF 33134-A, SKF-33134-A, Trangorex, VF-236', 'linkedDiseasesDrug_string': 'Ventricular Tachycardia (EFO_0005306), Atrial Fibrillation (EFO_0000275), Al Amyloidosis (MONDO_0019438), Heart Failure (EFO_0003144), Ventricular Fibrillation (EFO_0004287), Ventricular Arrhythmia (HP_0004308), Chagas Cardiomyopathy (EFO_0005529)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNH2 (ENSG00000055118)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1447 | Q17 | What gene does the drug Alfentanil target? | The drug Alfentanil targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alfentanil%" OR LOWER(tradeNames_string) LIKE "%alfentanil%" OR LOWER(drugSynonyms_string) LIKE "%alfentanil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_793', 'drugName': 'Alfentanil Hydrochloride', 'tradeNames_string': 'Alfenta, Alfentanil, Rapifen, Rapifen conc, Rapifen dilute, Rapifen intensive care', 'drugSynonyms_string': 'Alfentanil hydrochloride, Alfentanil hydrochloride cii, Alfentanil hydrochloride monohydrate, R 39,209, R 39209, R-39,209, R-39209', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2019', 'drugName': 'Alfentanil', 'tradeNames_string': '', 'drugSynonyms_string': 'Afentanyl, Alfentanil, Alfentanyl, IDS-NA-014, R-39209, R-39209-', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1782 | Q17 | What gene does the drug Rivoceranib Mesylate target? | The drug Rivoceranib Mesylate is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene KDR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rivoceranib mesylate%" OR LOWER(tradeNames_string) LIKE "%rivoceranib mesylate%" OR LOWER(drugSynonyms_string) LIKE "%rivoceranib mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_367', 'drugName': 'Rivoceranib Mesylate', 'tradeNames_string': 'Aitan', 'drugSynonyms_string': 'Apatinib (registered name in China), Apatinib mesylate, Rivoceranib mesylate, YN-968D1, Yn-968d1', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neuroblastoma (EFO_0000621), Medulloblastoma (EFO_0002939), Gestational Trophoblastic Neoplasm (MONDO_0018944), Adenoid Cystic Carcinoma (EFO_0000231), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Intrahepatic Cholangiocarcinoma (EFO_1001961), Lung Carcinoma (EFO_0001071), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Mouth Neoplasm (EFO_0003868), Ovarian Cancer (MONDO_0008170), Neuroendocrine Carcinoma (MONDO_0002120), Malignant Colon Neoplasm (MONDO_0021063), Gastric Cancer (MONDO_0001056), Breast Neoplasm (EFO_0003869), Hepatocellular Carcinoma (EFO_0000182), Ascites (HP_0001541), Differentiated Thyroid Carcinoma (EFO_1002017), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Gastric Adenocarcinoma (EFO_0000503), Gallbladder Carcinoma (EFO_1001956), Lymphoma (EFO_0000574), Cervical Carcinoma (EFO_0001061), Oral Squamous Cell Carcinoma (EFO_0000199), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Gastric Carcinoma (EFO_0000178), Malignant Glioma (MONDO_0100342), Metastasis (EFO_0009708), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Triple-Negative Breast Cancer (EFO_0005537), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Glioma (EFO_0005543), Carcinoma (EFO_0000313), Biliary Tract Neoplasm (EFO_0003891), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Liver Cancer (MONDO_0002691), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Stomach Neoplasm (EFO_0003897), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.468 | Q17 | What gene does the drug Dolasetron Mesylate target? | The drug Dolasetron Mesylate targets the gene HTR3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dolasetron mesylate%" OR LOWER(tradeNames_string) LIKE "%dolasetron mesylate%" OR LOWER(drugSynonyms_string) LIKE "%dolasetron mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2936', 'drugName': 'Dolasetron Mesylate', 'tradeNames_string': 'Anzemet', 'drugSynonyms_string': 'Dolasetron mesilate, Dolasetron mesilate monohydrate, Dolasetron mesylate, Dolasetron mesylate anhydrous, Dolasetron mesylate monohydrate, Dolasetron methanesulfonate, MDL 73,147EF, MDL-73147EF', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Post Operative Nausea And Vomiting (EFO_0004888), Nausea And Vomiting (HP_0002017)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1396 | Q17 | What gene does the drug Cerlapirdine target? | The drug Cerlapirdine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HTR6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cerlapirdine%" OR LOWER(tradeNames_string) LIKE "%cerlapirdine%" OR LOWER(drugSynonyms_string) LIKE "%cerlapirdine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5965', 'drugName': 'Cerlapirdine', 'tradeNames_string': '', 'drugSynonyms_string': 'Cerlapirdine, PF-05212365, SAM-531, SAM-531 FREE BASE, Sam-531, WAY-262,531, WAY-262531', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR6 (ENSG00000158748)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1614 | Q17 | What gene does the drug Abarelix target? | The drug Abarelix targets the gene GNRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%abarelix%" OR LOWER(tradeNames_string) LIKE "%abarelix%" OR LOWER(drugSynonyms_string) LIKE "%abarelix%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4834', 'drugName': 'Abarelix', 'tradeNames_string': 'Plenaxis', 'drugSynonyms_string': 'Abarelix, PPI-149, Plenaxis, R-382, R-3827, R382, R3827', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.549 | Q17 | What gene does the drug Aew-541 target? | The drug Aew-541 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IGF1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aew-541%" OR LOWER(tradeNames_string) LIKE "%aew-541%" OR LOWER(drugSynonyms_string) LIKE "%aew-541%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4582', 'drugName': 'Aew-541', 'tradeNames_string': '', 'drugSynonyms_string': 'AEW 541, Aew-541, NVP-AEW 541, NVP-AEW541', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.538 | Q17 | What gene does the drug Pegcetacoplan target? | The drug Pegcetacoplan targets the gene C3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pegcetacoplan%" OR LOWER(tradeNames_string) LIKE "%pegcetacoplan%" OR LOWER(drugSynonyms_string) LIKE "%pegcetacoplan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4931', 'drugName': 'Pegcetacoplan', 'tradeNames_string': 'Empaveli', 'drugSynonyms_string': 'APL-2, Pegcetacoplan', 'linkedDiseasesDrug_string': 'Dense Deposit Disease (MONDO_0019736), Amyotrophic Lateral Sclerosis (MONDO_0004976), Thrombotic Microangiopathy (MONDO_0019737), Immune System Disease (EFO_0000540), Age-Related Macular Degeneration (EFO_0001365)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'C3 (ENSG00000125730)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1230 | Q17 | What gene does the drug Ritodrine target? | The drug Ritodrine targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ritodrine%" OR LOWER(tradeNames_string) LIKE "%ritodrine%" OR LOWER(drugSynonyms_string) LIKE "%ritodrine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1499', 'drugName': 'Ritodrine', 'tradeNames_string': '', 'drugSynonyms_string': 'DU-21220, Ritodrine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5085', 'drugName': 'Ritodrine Hydrochloride', 'tradeNames_string': 'Ritodrine hydrochloride, Yutopar', 'drugSynonyms_string': 'Luteonin, NSC-291565, Ritodrine hcl, Ritodrine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.957 | Q17 | What gene does the drug Fontolizumab target? | The drug Fontolizumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IFNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fontolizumab%" OR LOWER(tradeNames_string) LIKE "%fontolizumab%" OR LOWER(drugSynonyms_string) LIKE "%fontolizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4201', 'drugName': 'Fontolizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'Fontolizumab, HUZAF', 'linkedDiseasesDrug_string': 'Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IFNG (ENSG00000111537)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1635 | Q17 | What gene does the drug Olmutinib target? | The drug Olmutinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%olmutinib%" OR LOWER(tradeNames_string) LIKE "%olmutinib%" OR LOWER(drugSynonyms_string) LIKE "%olmutinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2154', 'drugName': 'Olmutinib', 'tradeNames_string': '', 'drugSynonyms_string': 'BI 1482694, BI-1482694, HM-61713, HM61713, Hm-61713, Olmutinib', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1418 | Q17 | What gene does the drug Acarbose target? | The drug Acarbose targets 2 genes: AMY2A and MGAM. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acarbose%" OR LOWER(tradeNames_string) LIKE "%acarbose%" OR LOWER(drugSynonyms_string) LIKE "%acarbose%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1144', 'drugName': 'Acarbose', 'tradeNames_string': 'Acarbose, Glucobay, Precose', 'drugSynonyms_string': 'Acarbose, BAY G 5421, BAY-G-5421, NSC-758915', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Orthostatic Hypotension (EFO_0005252), Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Obesity (EFO_0001073), Kidney Cancer (MONDO_0002367), Gestational Diabetes (EFO_0004593), Hypercholesterolemia (HP_0003124), Metabolic Syndrome (EFO_0000195), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Aging (GO_0007568), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914), Metabolic Disease (EFO_0000589), Hyperinsulinemic Hypoglycemia (EFO_0007318)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AMY2A (ENSG00000243480), MGAM (ENSG00000257335)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1145', 'drugName': 'Acarbose', 'tradeNames_string': 'Acarbose, Glucobay, Precose', 'drugSynonyms_string': 'Acarbose, BAY G 5421, BAY-G-5421, NSC-758915', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Orthostatic Hypotension (EFO_0005252), Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Obesity (EFO_0001073), Kidney Cancer (MONDO_0002367), Gestational Diabetes (EFO_0004593), Hypercholesterolemia (HP_0003124), Metabolic Syndrome (EFO_0000195), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Aging (GO_0007568), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914), Metabolic Disease (EFO_0000589), Hyperinsulinemic Hypoglycemia (EFO_0007318)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AMY2A (ENSG00000243480), MGAM (ENSG00000257335)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.422 | Q17 | What gene does the drug Ecallantide target? | The drug Ecallantide targets the gene KLKB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ecallantide%" OR LOWER(tradeNames_string) LIKE "%ecallantide%" OR LOWER(drugSynonyms_string) LIKE "%ecallantide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2279', 'drugName': 'Ecallantide', 'tradeNames_string': '', 'drugSynonyms_string': 'DX-88, Ecallantide, Escallantide', 'linkedDiseasesDrug_string': 'Angioedema (EFO_0005532), Hereditary Angioedema (MONDO_0019623)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KLKB1 (ENSG00000164344)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1935 | Q17 | What gene does the drug Hydrocortisone Valerate target? | The drug Hydrocortisone Valerate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydrocortisone valerate%" OR LOWER(tradeNames_string) LIKE "%hydrocortisone valerate%" OR LOWER(drugSynonyms_string) LIKE "%hydrocortisone valerate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1914', 'drugName': 'Hydrocortisone Valerate', 'tradeNames_string': 'Hydrocortisone valerate, Westcort', 'drugSynonyms_string': 'Cortisol 17-valerate, Hydrocortisone 17-valerate, Hydrocortisone valerate, NSC-759133', 'linkedDiseasesDrug_string': 'Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1532 | Q17 | What gene does the drug Moricizine target? | The drug Moricizine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%moricizine%" OR LOWER(tradeNames_string) LIKE "%moricizine%" OR LOWER(drugSynonyms_string) LIKE "%moricizine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4424', 'drugName': 'Moricizine', 'tradeNames_string': 'Ethmozine', 'drugSynonyms_string': 'EN-313, EN-313 FREE BASE, Ethmozine, Moracizine, Moricizine', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_2214', 'drugName': 'Moricizine Hydrochloride', 'tradeNames_string': 'Ethmozine', 'drugSynonyms_string': 'Moracizine hydrochloride, Moricizine hcl, Moricizine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1580 | Q17 | What gene does the drug Scy 635 target? | The drug Scy 635 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PPIA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%scy 635%" OR LOWER(tradeNames_string) LIKE "%scy 635%" OR LOWER(drugSynonyms_string) LIKE "%scy 635%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5084', 'drugName': 'Scy 635', 'tradeNames_string': '', 'drugSynonyms_string': 'SCY-635, Scy 635', 'linkedDiseasesDrug_string': 'Chronic Hepatitis C Virus Infection (EFO_0004220), Hepatitis C Virus Infection (EFO_0003047)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PPIA (ENSG00000196262)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1659 | Q17 | What gene does the drug Metoprolol Tartrate target? | The drug Metoprolol Tartrate targets the gene ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%metoprolol tartrate%" OR LOWER(tradeNames_string) LIKE "%metoprolol tartrate%" OR LOWER(drugSynonyms_string) LIKE "%metoprolol tartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1301', 'drugName': 'Metoprolol Tartrate', 'tradeNames_string': 'Arbralene, Beloc cor, Betaloc, Betaloc s.a., Lopresor, Lopresor sr, Lopressor, Mepranix 100, Mepranix 50, Metoprolol tartrate, Tensomex, Toprol xl', 'drugSynonyms_string': 'Beloc, CGP-2175E, Metoprolol hemitartrate, Metoprolol tartrate, Metropress, NSC-757105, Prelis, Seloken, Selopral', 'linkedDiseasesDrug_string': 'Heart Disease (EFO_0003777), Angina Pectoris (EFO_0003913), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1116 | Q17 | What gene does the drug Crisaborole target? | The drug Crisaborole targets 4 genes: PDE4A, PDE4D, PDE4B and PDE4C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%crisaborole%" OR LOWER(tradeNames_string) LIKE "%crisaborole%" OR LOWER(drugSynonyms_string) LIKE "%crisaborole%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5927', 'drugName': 'Crisaborole', 'tradeNames_string': 'Eucrisa', 'drugSynonyms_string': 'AN-2728, AN2728, Crisaborole', 'linkedDiseasesDrug_string': 'Eczema (HP_0000964), Psoriasis (EFO_0000676), Localised Scleroderma (EFO_1001361), Vitiligo (EFO_0004208), Alopecia Areata (EFO_0004192), Atopic Eczema (EFO_0000274), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.722 | Q17 | What gene does the drug D-3263 target? | The drug D-3263 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TRPM8. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%d-3263%" OR LOWER(tradeNames_string) LIKE "%d-3263%" OR LOWER(drugSynonyms_string) LIKE "%d-3263%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2716', 'drugName': 'D-3263', 'tradeNames_string': '', 'drugSynonyms_string': 'D 3263, D-3263, D-3263 (FREE BASE)', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'TRPM8 (ENSG00000144481)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1247 | Q17 | What gene does the drug Levobupivacaine Hydrochloride target? | The drug Levobupivacaine Hydrochloride targets the gene SCN4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levobupivacaine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%levobupivacaine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%levobupivacaine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4768', 'drugName': 'Levobupivacaine Hydrochloride', 'tradeNames_string': 'Chirocaine, Levobupivac', 'drugSynonyms_string': 'Bupivacaine (-)-form hydrochloride, CHIROCAINE, Levobupivacaine hcl, Levobupivacaine hydrochloride', 'linkedDiseasesDrug_string': 'Pregnancy (EFO_0002950), Pain (EFO_0003843)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN4A (ENSG00000007314)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1236 | Q17 | What gene does the drug Bismuth Subsalicylate target? | The drug Bismuth Subsalicylate targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bismuth subsalicylate%" OR LOWER(tradeNames_string) LIKE "%bismuth subsalicylate%" OR LOWER(drugSynonyms_string) LIKE "%bismuth subsalicylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1367', 'drugName': 'Bismuth Subsalicylate', 'tradeNames_string': 'Bismukote, Corrective Suspension, Gastro-Cote, Pepto-Bismol', 'drugSynonyms_string': 'Bismuth salicylate, Bismuth subsalicylate, NSC-759117', 'linkedDiseasesDrug_string': 'Helicobacter Pylori Infectious Disease (EFO_1000961), Diarrhea (HP_0002014), Nausea (HP_0002018), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1076 | Q17 | What gene does the drug Atenolol target? | The drug Atenolol targets the gene ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%atenolol%" OR LOWER(tradeNames_string) LIKE "%atenolol%" OR LOWER(drugSynonyms_string) LIKE "%atenolol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_589', 'drugName': 'Atenolol', 'tradeNames_string': 'Antipressan, Atenamin, Atenix-100, Atenix-25, Atenix-50, Atenolol, Ibinolo, Kentol, Tenormin, Tenormin 25, Tenormin l.s., Totamol, Unibloc, Vasaten', 'drugSynonyms_string': 'Atenolol, Atenololum, Betacard, C07AB03, Corotenol, Duraatenolol, Esatenolol, ICI 66,082, ICI 66082, ICI-66082, Juvental, Myocord, NSC-757832, Novaten, Prenormine, Urosin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Essential Hypertension (MONDO_0001134), Atrial Fibrillation (EFO_0000275), Osteoporosis (EFO_0003882), Post-Traumatic Stress Disorder (EFO_0001358), Myocardial Ischemia (EFO_1001375), Angina Pectoris (EFO_0003913), Left Ventricular Hypertrophy (EFO_0003896), Coronary Atherosclerosis (MONDO_0021661), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Stroke (EFO_0000712), Hemangioma (EFO_1000635), Myocardial Infarction (EFO_0000612), Cerebrovascular Disorder (EFO_0003763), Marfan Syndrome (MONDO_0007947), Heart Disease (EFO_0003777), Heart Failure (EFO_0003144), Mitral Valve Stenosis (EFO_0007372)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1907 | Q17 | What gene does the drug Idrevloride target? | The drug Idrevloride is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: SCNN1B, SCNN1A and SCNN1G | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%idrevloride%" OR LOWER(tradeNames_string) LIKE "%idrevloride%" OR LOWER(drugSynonyms_string) LIKE "%idrevloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4187', 'drugName': 'Idrevloride', 'tradeNames_string': '', 'drugSynonyms_string': 'GS-560876, GS-5737, Idrevloride, P-1037, VRT-1499138, VX-371', 'linkedDiseasesDrug_string': 'Cystic Fibrosis (MONDO_0009061)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SCNN1A (ENSG00000111319), SCNN1B (ENSG00000168447), SCNN1G (ENSG00000166828)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.264 | Q17 | What gene does the drug Camoteskimab target? | The drug Camoteskimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL18. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%camoteskimab%" OR LOWER(tradeNames_string) LIKE "%camoteskimab%" OR LOWER(drugSynonyms_string) LIKE "%camoteskimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6087', 'drugName': 'Camoteskimab', 'tradeNames_string': '', 'drugSynonyms_string': 'AEVI-007, Aevi-007, CERC-007, Camoteskimab, MEDI-2338, MEDI2338, Medi-2338', 'linkedDiseasesDrug_string': "Adult-Onset Still'S Disease (EFO_0007135), Multiple Myeloma (EFO_0001378), Chronic Obstructive Pulmonary Disease (EFO_0000341)", 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL18 (ENSG00000150782)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1437 | Q17 | What gene does the drug Ganaxolone target? | The drug Ganaxolone targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ganaxolone%" OR LOWER(tradeNames_string) LIKE "%ganaxolone%" OR LOWER(drugSynonyms_string) LIKE "%ganaxolone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1369', 'drugName': 'Ganaxolone', 'tradeNames_string': 'Ztalmy', 'drugSynonyms_string': 'CCD 1042, CCD-1042, DEA NO. 2401, Ganaxolone, Ztalmy', 'linkedDiseasesDrug_string': 'Post-Traumatic Stress Disorder (EFO_0001358), Smoking Cessation (EFO_0004319), West Syndrome (MONDO_0018097), Fragile X Syndrome (MONDO_0010383), Partial Epilepsy (EFO_0004263), Tuberous Sclerosis (MONDO_0001734), Epilepsy (EFO_0000474), Seizure (HP_0001250), Status Epilepticus (EFO_0008526), Complex Partial Epilepsy (EFO_1000877)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1339 | Q17 | What gene does the drug Naphazoline target? | The drug Naphazoline targets 6 genes: ADRA2A, ADRA2C, ADRA1A, ADRA1D, ADRA2B and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%naphazoline%" OR LOWER(tradeNames_string) LIKE "%naphazoline%" OR LOWER(drugSynonyms_string) LIKE "%naphazoline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_327', 'drugName': 'Naphazoline Hydrochloride', 'tradeNames_string': 'Albalon, Antistin-privine, Gppe nsl soln, Nafazair, Naphaz hcl, Naphazoline hydrochloride, Naphcon, Naphcon forte, Opcon, Vasocon', 'drugSynonyms_string': 'NSC-35711, Naphazoline HCl, Naphazoline hcl, Naphazoline hydrochloride, Naphazoline nitrate', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Common Cold (EFO_0007214), Seasonal Allergic Rhinitis (EFO_0003956), Inflammation (MP_0001845), Influenza (EFO_0007328), Nasal Congestion (HP_0001742), Pterygium (EFO_0000678)', 'yearOfFirstApproval': 1971, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_4828', 'drugName': 'Naphazoline', 'tradeNames_string': '', 'drugSynonyms_string': 'Nafazair, Nafazolin, Naphazoline', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Sinusitis (EFO_0007486), Common Cold (EFO_0007214), Neoplasm (EFO_0000616), Seasonal Allergic Rhinitis (EFO_0003956), Inflammation (MP_0001845), Hyperemia (EFO_0003822), Influenza (EFO_0007328), Nasal Congestion (HP_0001742), Eye Allergy (EFO_0005751), Pterygium (EFO_0000678)', 'yearOfFirstApproval': 1971, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.243 | Q17 | What gene does the drug Benazepril target? | The drug Benazepril targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benazepril%" OR LOWER(tradeNames_string) LIKE "%benazepril%" OR LOWER(drugSynonyms_string) LIKE "%benazepril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5353', 'drugName': 'Benazepril Hydrochloride', 'tradeNames_string': 'Benazepril hydrochloride, Cibacen, Lotensin', 'drugSynonyms_string': 'Benazepril hcl, Benazepril hydrochloride, CGS 14824A HCL, CGS-14824A, CGS-14824A HCL, NSC-758920', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Henoch-Schoenlein Purpura (EFO_1000965), Stroke (EFO_0000712), Hypertension (EFO_0000537), Fish-Eye Disease (Orphanet_79292), Kidney Disease (EFO_0003086), Kidney Failure (EFO_1002048), X-Linked Alport Syndrome (MONDO_0010520)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5259', 'drugName': 'Benazepril', 'tradeNames_string': '', 'drugSynonyms_string': 'Benazepril, Benazepril sandoz, Briem, C09AA07, CGS-14824A, Cibacen ws, Cibacene, Forteekor, Lotensin, Lotrel', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Henoch-Schoenlein Purpura (EFO_1000965), Coronary Artery Disease (EFO_0001645), Stroke (EFO_0000712), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Kidney Disease (EFO_0003086), Fish-Eye Disease (Orphanet_79292), Kidney Failure (EFO_1002048), Systemic Lupus Erythematosus (MONDO_0007915), Alport Syndrome (MONDO_0018965), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914), X-Linked Alport Syndrome (MONDO_0010520)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1010 | Q17 | What gene does the drug Tizanidine target? | The drug Tizanidine targets 3 genes: ADRA2A, ADRA2C and ADRA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tizanidine%" OR LOWER(tradeNames_string) LIKE "%tizanidine%" OR LOWER(drugSynonyms_string) LIKE "%tizanidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5012', 'drugName': 'Tizanidine Hydrochloride', 'tradeNames_string': 'Sirdalud, Sirdalud mr, Tizanidine hydrochloride, Zanaflex', 'drugSynonyms_string': 'AN-021, AN021, DS 103-282, DS-103-282, Tizanidine (as hydrochloride), Tizanidine hcl, Tizanidine hydrochloride', 'linkedDiseasesDrug_string': 'Migraine With Aura (MONDO_0005475), Migraine Without Aura (MONDO_0100431), Radiculopathy (MONDO_0002959), Spasticity (HP_0001257), Brain Injury (MONDO_0043510)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3385', 'drugName': 'Tizanidine', 'tradeNames_string': '', 'drugSynonyms_string': 'Tizanidine, Zanaflex', 'linkedDiseasesDrug_string': 'Migraine Without Aura (MONDO_0100431), Migraine With Aura (MONDO_0005475), Pain (EFO_0003843), Radiculopathy (MONDO_0002959), Melanoma (EFO_0000756), Spasticity (HP_0001257), Brain Injury (MONDO_0043510)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.685 | Q17 | What gene does the drug Pf-03654764 target? | The drug Pf-03654764 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HRH3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pf-03654764%" OR LOWER(tradeNames_string) LIKE "%pf-03654764%" OR LOWER(drugSynonyms_string) LIKE "%pf-03654764%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3431', 'drugName': 'Pf-03654764', 'tradeNames_string': '', 'drugSynonyms_string': 'Pf-03654764', 'linkedDiseasesDrug_string': 'Allergic Rhinitis (EFO_0005854)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HRH3 (ENSG00000101180)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1268 | Q17 | What gene does the drug Chlorphentermine Hydrochloride target? | The drug Chlorphentermine Hydrochloride targets the gene SLC6A4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%chlorphentermine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%chlorphentermine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%chlorphentermine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4353', 'drugName': 'Chlorphentermine Hydrochloride', 'tradeNames_string': 'Pre-sate', 'drugSynonyms_string': 'Chlorphentermine hcl, Chlorphentermine hydrochloride, NSC-76098, S-62, W 2426, W-2426', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1475 | Q17 | What gene does the drug Tropicamide target? | The drug Tropicamide targets the gene CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tropicamide%" OR LOWER(tradeNames_string) LIKE "%tropicamide%" OR LOWER(drugSynonyms_string) LIKE "%tropicamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1110', 'drugName': 'Tropicamide', 'tradeNames_string': 'Mydriacyl, Mydriafair, Nods, Tropicacyl, Tropicamide', 'drugSynonyms_string': 'Bistropamide, NSC-757372, RO-1-7683, Tropicamide, Tropicamidum, Visumidriatic', 'linkedDiseasesDrug_string': 'Mydriasis (HP_0011499), Presbyopia (MONDO_0001330), Eye Disease (EFO_0003966), Drooling (HP_0002307), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1502 | Q17 | What gene does the drug Desvenlafaxine Fumarate target? | The drug Desvenlafaxine Fumarate targets 2 genes: SLC6A4 and SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%desvenlafaxine fumarate%" OR LOWER(tradeNames_string) LIKE "%desvenlafaxine fumarate%" OR LOWER(drugSynonyms_string) LIKE "%desvenlafaxine fumarate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5873', 'drugName': 'Desvenlafaxine Fumarate', 'tradeNames_string': '', 'drugSynonyms_string': 'Desvenlafaxine fumarate, Desvenlafaxine fumarate anhydrous, O-desmethylvenlafaxine fumarate', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5874', 'drugName': 'Desvenlafaxine Fumarate', 'tradeNames_string': '', 'drugSynonyms_string': 'Desvenlafaxine fumarate, Desvenlafaxine fumarate anhydrous, O-desmethylvenlafaxine fumarate', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.370 | Q17 | What gene does the drug Nafarelin target? | The drug Nafarelin targets the gene GNRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nafarelin%" OR LOWER(tradeNames_string) LIKE "%nafarelin%" OR LOWER(drugSynonyms_string) LIKE "%nafarelin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_992', 'drugName': 'Nafarelin', 'tradeNames_string': '', 'drugSynonyms_string': 'Lhrh, 6(d-nal(2)), Nafarelin', 'linkedDiseasesDrug_string': 'Endometriosis (EFO_0001065), Pain (EFO_0003843), Infertility (EFO_0000545)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_669', 'drugName': 'Nafarelin Acetate', 'tradeNames_string': 'Synarel', 'drugSynonyms_string': 'Nafarelin acetate, Nafarelin acetate anhydrous, Nafarelin acetate hydrate, Nasanyl, RS-94991, RS-94991-298', 'linkedDiseasesDrug_string': 'Endometriosis (EFO_0001065)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1009 | Q17 | What gene does the drug Bevenopran target? | The drug Bevenopran is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bevenopran%" OR LOWER(tradeNames_string) LIKE "%bevenopran%" OR LOWER(drugSynonyms_string) LIKE "%bevenopran%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3338', 'drugName': 'Bevenopran', 'tradeNames_string': '', 'drugSynonyms_string': 'ADL-5945, ADL5945, Bevenopran, CB-5945, CB5-945, CB5945', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Constipation (HP_0002019)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1239 | Q17 | What gene does the drug Methylergonovine Maleate target? | The drug Methylergonovine Maleate targets 2 genes: HTR2B and DRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methylergonovine maleate%" OR LOWER(tradeNames_string) LIKE "%methylergonovine maleate%" OR LOWER(drugSynonyms_string) LIKE "%methylergonovine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2336', 'drugName': 'Methylergonovine Maleate', 'tradeNames_string': 'Methergine, Methylergonovine maleate', 'drugSynonyms_string': 'Methylergometrine maleate, Methylergonovine maleate, Methylergonovinium bimaleate, NSC-757104', 'linkedDiseasesDrug_string': 'Hemorrhage (MP_0001914)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD1 (ENSG00000184845), HTR2B (ENSG00000135914)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2337', 'drugName': 'Methylergonovine Maleate', 'tradeNames_string': 'Methergine, Methylergonovine maleate', 'drugSynonyms_string': 'Methylergometrine maleate, Methylergonovine maleate, Methylergonovinium bimaleate, NSC-757104', 'linkedDiseasesDrug_string': 'Hemorrhage (MP_0001914)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD1 (ENSG00000184845), HTR2B (ENSG00000135914)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.595 | Q17 | What gene does the drug Momelotinib target? | The drug Momelotinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: JAK1 and JAK2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%momelotinib%" OR LOWER(tradeNames_string) LIKE "%momelotinib%" OR LOWER(drugSynonyms_string) LIKE "%momelotinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1654', 'drugName': 'Momelotinib', 'tradeNames_string': '', 'drugSynonyms_string': 'CYT-0387, CYT-11387, CYT-387, CYT387, Cyt-387, GS-0387, Momelotinib', 'linkedDiseasesDrug_string': 'Primary Myelofibrosis (EFO_0002430), Essential Thrombocythemia (EFO_0000479), Non-Small Cell Lung Carcinoma (EFO_0003060), Myelofibrosis (MONDO_0044903), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Polycythemia Vera (EFO_0002429)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434), JAK2 (ENSG00000096968)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1655', 'drugName': 'Momelotinib', 'tradeNames_string': '', 'drugSynonyms_string': 'CYT-0387, CYT-11387, CYT-387, CYT387, Cyt-387, GS-0387, Momelotinib', 'linkedDiseasesDrug_string': 'Primary Myelofibrosis (EFO_0002430), Essential Thrombocythemia (EFO_0000479), Non-Small Cell Lung Carcinoma (EFO_0003060), Myelofibrosis (MONDO_0044903), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Polycythemia Vera (EFO_0002429)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434), JAK2 (ENSG00000096968)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.728 | Q17 | What gene does the drug Bemiparin Sodium target? | The drug Bemiparin Sodium targets the gene SERPINC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bemiparin sodium%" OR LOWER(tradeNames_string) LIKE "%bemiparin sodium%" OR LOWER(drugSynonyms_string) LIKE "%bemiparin sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2284', 'drugName': 'Bemiparin Sodium', 'tradeNames_string': 'Zibor', 'drugSynonyms_string': 'Badyket, Bemiparin sodium, Hibor, Zivor', 'linkedDiseasesDrug_string': 'Deep Vein Thrombosis (EFO_0003907), Covid-19 (MONDO_0100096)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SERPINC1 (ENSG00000117601)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.486 | Q17 | What gene does the drug Chlorphenoxamine target? | The drug Chlorphenoxamine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%chlorphenoxamine%" OR LOWER(tradeNames_string) LIKE "%chlorphenoxamine%" OR LOWER(drugSynonyms_string) LIKE "%chlorphenoxamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6059', 'drugName': 'Chlorphenoxamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Chlorphenoxamine', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271), Pruritus (HP_0000989)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.573 | Q17 | What gene does the drug Tinzaparin Sodium target? | The drug Tinzaparin Sodium targets the gene SERPINC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tinzaparin sodium%" OR LOWER(tradeNames_string) LIKE "%tinzaparin sodium%" OR LOWER(drugSynonyms_string) LIKE "%tinzaparin sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3678', 'drugName': 'Tinzaparin Sodium', 'tradeNames_string': 'Innohep, Logiparin', 'drugSynonyms_string': 'LNH-1, LNH1, Tinzaparin, Tinzaparin na, Tinzaparin sodium, Tinzaparin sodium, porcine', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Multiple Myeloma (EFO_0001378), Ischemic Stroke (HP_0002140), Pneumonia (EFO_0003106), Colorectal Adenocarcinoma (EFO_0000365), Deep Vein Thrombosis (EFO_0003907), Covid-19 (MONDO_0100096), Kidney Cancer (MONDO_0002367), Non-Small Cell Lung Carcinoma (EFO_0003060), Thromboembolism (HP_0001907), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SERPINC1 (ENSG00000117601)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.74 | Q17 | What gene does the drug Norelgestromin target? | The drug Norelgestromin targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%norelgestromin%" OR LOWER(tradeNames_string) LIKE "%norelgestromin%" OR LOWER(drugSynonyms_string) LIKE "%norelgestromin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2301', 'drugName': 'Norelgestromin', 'tradeNames_string': 'Evra, Ortho evra', 'drugSynonyms_string': 'Deacetylnorgestimate, Norelgestromin, RWJ-10553', 'linkedDiseasesDrug_string': 'Pregnancy (EFO_0002950), Metrorrhagia (HP_0100608), Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.635 | Q17 | What gene does the drug Zanubrutinib target? | The drug Zanubrutinib targets the gene BTK. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zanubrutinib%" OR LOWER(tradeNames_string) LIKE "%zanubrutinib%" OR LOWER(drugSynonyms_string) LIKE "%zanubrutinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2717', 'drugName': 'Zanubrutinib', 'tradeNames_string': 'Brukinsa', 'drugSynonyms_string': 'BGB-3111, Bgb-3111, Zanubrutinib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Follicular Lymphoma (MONDO_0018906), Mantle Cell Lymphoma (EFO_1001469), Chronic Lymphocytic Leukemia (EFO_0000095), Neoplasm (EFO_0000616), Neoplasm Of Mature B-Cells (EFO_0000096), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Leukemia (EFO_0000565), Covid-19 (MONDO_0100096), Neuromyelitis Optica (EFO_0004256), Hemophagocytic Syndrome (MONDO_0015540), Lymphoma (EFO_0000574), Waldenstrom Macroglobulinemia (EFO_0009441), Castleman Disease (MONDO_0015564), Diffuse Large B-Cell Lymphoma (EFO_0000403), Lupus Nephritis (EFO_0005761), Igg4-Related Disease (MONDO_0017287)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BTK (ENSG00000010671)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.262 | Q17 | What gene does the drug Azd-1236 target? | The drug Azd-1236 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: MMP9 and MMP12 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azd-1236%" OR LOWER(tradeNames_string) LIKE "%azd-1236%" OR LOWER(drugSynonyms_string) LIKE "%azd-1236%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1156', 'drugName': 'Azd-1236', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD1236, Azd 1236, Azd-1236, Azd1236', 'linkedDiseasesDrug_string': 'Cystic Fibrosis (MONDO_0009061), Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP12 (ENSG00000262406)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1157', 'drugName': 'Azd-1236', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD1236, Azd 1236, Azd-1236, Azd1236', 'linkedDiseasesDrug_string': 'Cystic Fibrosis (MONDO_0009061), Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MMP9 (ENSG00000100985), MMP12 (ENSG00000262406)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.52 | Q17 | What gene does the drug Imipramine Hydrochloride target? | The drug Imipramine Hydrochloride targets 2 genes: SLC6A4 and SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%imipramine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%imipramine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%imipramine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3837', 'drugName': 'Imipramine Hydrochloride', 'tradeNames_string': 'Imipramine hydrochloride, Janimine, Pramine, Praminil, Presamine, Sarimp, Tofranil', 'drugSynonyms_string': 'G-22355, Imidobenzyle, Imipramine HCl, Imipramine hcl, Imipramine hydrochloride, Imipramine hydrochloride rs, Imipramini hydrochloridum, Imizine, NSC-114900, Pryleugan', 'linkedDiseasesDrug_string': 'Depressive Disorder (MONDO_0002050), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3838', 'drugName': 'Imipramine Hydrochloride', 'tradeNames_string': 'Imipramine hydrochloride, Janimine, Pramine, Praminil, Presamine, Sarimp, Tofranil', 'drugSynonyms_string': 'G-22355, Imidobenzyle, Imipramine HCl, Imipramine hcl, Imipramine hydrochloride, Imipramine hydrochloride rs, Imipramini hydrochloridum, Imizine, NSC-114900, Pryleugan', 'linkedDiseasesDrug_string': 'Depressive Disorder (MONDO_0002050), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.201 | Q17 | What gene does the drug Serplulimab target? | The drug Serplulimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PDCD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%serplulimab%" OR LOWER(tradeNames_string) LIKE "%serplulimab%" OR LOWER(drugSynonyms_string) LIKE "%serplulimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1285', 'drugName': 'Serplulimab', 'tradeNames_string': '', 'drugSynonyms_string': 'HLX-10, HLX10, Hlx10, Serplulimab', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Ascites (HP_0001541), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Cervical Cancer (MONDO_0002974)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDCD1 (ENSG00000188389)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.432 | Q17 | What gene does the drug Otamixaban target? | The drug Otamixaban is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene F10. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%otamixaban%" OR LOWER(tradeNames_string) LIKE "%otamixaban%" OR LOWER(drugSynonyms_string) LIKE "%otamixaban%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3113', 'drugName': 'Otamixaban', 'tradeNames_string': '', 'drugSynonyms_string': 'FXV-673, Fxv673, Otamixaban, RPR-130673, RPR130673, XRP-0673, XRP0673', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Liver Disease (EFO_0001421), Coronary Artery Disease (EFO_0001645), Acute Coronary Syndrome (EFO_0005672)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'F10 (ENSG00000126218)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1563 | Q17 | What gene does the drug Dromostanolone Propionate target? | The drug Dromostanolone Propionate targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dromostanolone propionate%" OR LOWER(tradeNames_string) LIKE "%dromostanolone propionate%" OR LOWER(drugSynonyms_string) LIKE "%dromostanolone propionate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2428', 'drugName': 'Dromostanolone Propionate', 'tradeNames_string': 'Drolban, Masteril', 'drugSynonyms_string': '32379, Dromostanolone, Dromostanolone propionate, Drostanolone, Drostanolone propionate, Masterid, Masteron, NSC-12198, NSC-1298, Permastril', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.336 | Q17 | What gene does the drug Fosbretabulin target? | The drug Fosbretabulin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 15 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fosbretabulin%" OR LOWER(tradeNames_string) LIKE "%fosbretabulin%" OR LOWER(drugSynonyms_string) LIKE "%fosbretabulin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3390', 'drugName': 'Fosbretabulin', 'tradeNames_string': '', 'drugSynonyms_string': 'Combretastatin a-4 phosphate, Combretastatin a4 phosphate, Fosbretabulin, Phosbretabulin', 'linkedDiseasesDrug_string': 'Neuroendocrine Neoplasm (EFO_1001901), Cancer (MONDO_0004992), Head And Neck Malignant Neoplasia (EFO_0006859), Neoplasm (EFO_0000616), Wet Macular Degeneration (EFO_0004683), Thyroid Cancer (MONDO_0002108), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}, {'UUID': 'DrugGeneTargets_v2_3391', 'drugName': 'Fosbretabulin', 'tradeNames_string': '', 'drugSynonyms_string': 'Combretastatin a-4 phosphate, Combretastatin a4 phosphate, Fosbretabulin, Phosbretabulin', 'linkedDiseasesDrug_string': 'Neuroendocrine Neoplasm (EFO_1001901), Cancer (MONDO_0004992), Head And Neck Malignant Neoplasia (EFO_0006859), Neoplasm (EFO_0000616), Wet Macular Degeneration (EFO_0004683), Thyroid Cancer (MONDO_0002108), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}, {'UUID': 'DrugGeneTargets_v2_4395', 'drugName': 'Fosbretabulin Tromethamine', 'tradeNames_string': 'Zybrestat', 'drugSynonyms_string': 'Fosbretabulin tromethamine', 'linkedDiseasesDrug_string': 'Neuroendocrine Neoplasm (EFO_1001901), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}, {'UUID': 'DrugGeneTargets_v2_5130', 'drugName': 'Fosbretabulin Disodium', 'tradeNames_string': '', 'drugSynonyms_string': 'CA 4P, CA-4DP, CA4DP, Fosbretabulin disodium, Fosbretabulin disodium salt', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Head And Neck Malignant Neoplasia (EFO_0006859), Wet Macular Degeneration (EFO_0004683), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1557 | Q17 | What gene does the drug Linifanib target? | The drug Linifanib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 7 genes: FLT3, FLT4, FLT1, KDR, CSF1R, PDGFRB and PDGFRA | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%linifanib%" OR LOWER(tradeNames_string) LIKE "%linifanib%" OR LOWER(drugSynonyms_string) LIKE "%linifanib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1027', 'drugName': 'Linifanib', 'tradeNames_string': '', 'drugSynonyms_string': 'A-741439, ABT-869, AL-39324, Linifanib, RG-3635', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Renal Cell Carcinoma (EFO_0000681), Endometriosis (EFO_0001065), Age-Related Macular Degeneration (EFO_0001365), Malignant Colon Neoplasm (MONDO_0021063)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_1026', 'drugName': 'Linifanib', 'tradeNames_string': '', 'drugSynonyms_string': 'A-741439, ABT-869, AL-39324, Linifanib, RG-3635', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Renal Cell Carcinoma (EFO_0000681), Endometriosis (EFO_0001065), Age-Related Macular Degeneration (EFO_0001365), Malignant Colon Neoplasm (MONDO_0021063)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_1029', 'drugName': 'Linifanib', 'tradeNames_string': '', 'drugSynonyms_string': 'A-741439, ABT-869, AL-39324, Linifanib, RG-3635', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Renal Cell Carcinoma (EFO_0000681), Endometriosis (EFO_0001065), Age-Related Macular Degeneration (EFO_0001365), Malignant Colon Neoplasm (MONDO_0021063)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_1028', 'drugName': 'Linifanib', 'tradeNames_string': '', 'drugSynonyms_string': 'A-741439, ABT-869, AL-39324, Linifanib, RG-3635', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Renal Cell Carcinoma (EFO_0000681), Endometriosis (EFO_0001065), Age-Related Macular Degeneration (EFO_0001365), Malignant Colon Neoplasm (MONDO_0021063)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1539 | Q17 | What gene does the drug Levalbuterol Hydrochloride target? | The drug Levalbuterol Hydrochloride targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levalbuterol hydrochloride%" OR LOWER(tradeNames_string) LIKE "%levalbuterol hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%levalbuterol hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1198', 'drugName': 'Levalbuterol Hydrochloride', 'tradeNames_string': 'Levalbuterol hydrochloride, Xopenex', 'drugSynonyms_string': 'Albuterol (r)-form hydrochloride, Albuterol hydrochloride, r-, Levalbuterol hcl, Levalbuterol hydrochloride, Levosalbutamol hydrochloride, NSC-759255', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.426 | Q17 | What gene does the drug Kn-026 target? | The drug Kn-026 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ERBB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kn-026%" OR LOWER(tradeNames_string) LIKE "%kn-026%" OR LOWER(drugSynonyms_string) LIKE "%kn-026%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_241', 'drugName': 'Kn-026', 'tradeNames_string': '', 'drugSynonyms_string': 'Anbenitamab, Anti-her2 bsab kn026, KN-026, KN026, Kn 026, Kn-026, Kn026', 'linkedDiseasesDrug_string': 'Gastric Cancer (MONDO_0001056), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.637 | Q17 | What gene does the drug Cep-1347 target? | The drug Cep-1347 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 5 genes: MAP3K10, MAP3K13, MAP3K11, MAP3K12 and MAP3K9 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cep-1347%" OR LOWER(tradeNames_string) LIKE "%cep-1347%" OR LOWER(drugSynonyms_string) LIKE "%cep-1347%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6091', 'drugName': 'Cep-1347', 'tradeNames_string': '', 'drugSynonyms_string': 'CEP-1347, Cep-1347, KT-1575, KT-7515, KT7515', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAP3K13 (ENSG00000073803), MAP3K12 (ENSG00000139625), MAP3K10 (ENSG00000130758), MAP3K9 (ENSG00000006432), MAP3K11 (ENSG00000173327)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_6088', 'drugName': 'Cep-1347', 'tradeNames_string': '', 'drugSynonyms_string': 'CEP-1347, Cep-1347, KT-1575, KT-7515, KT7515', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAP3K13 (ENSG00000073803), MAP3K12 (ENSG00000139625), MAP3K10 (ENSG00000130758), MAP3K9 (ENSG00000006432), MAP3K11 (ENSG00000173327)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_6089', 'drugName': 'Cep-1347', 'tradeNames_string': '', 'drugSynonyms_string': 'CEP-1347, Cep-1347, KT-1575, KT-7515, KT7515', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAP3K13 (ENSG00000073803), MAP3K12 (ENSG00000139625), MAP3K10 (ENSG00000130758), MAP3K9 (ENSG00000006432), MAP3K11 (ENSG00000173327)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_6092', 'drugName': 'Cep-1347', 'tradeNames_string': '', 'drugSynonyms_string': 'CEP-1347, Cep-1347, KT-1575, KT-7515, KT7515', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAP3K13 (ENSG00000073803), MAP3K12 (ENSG00000139625), MAP3K10 (ENSG00000130758), MAP3K9 (ENSG00000006432), MAP3K11 (ENSG00000173327)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_6090', 'drugName': 'Cep-1347', 'tradeNames_string': '', 'drugSynonyms_string': 'CEP-1347, Cep-1347, KT-1575, KT-7515, KT7515', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAP3K13 (ENSG00000073803), MAP3K12 (ENSG00000139625), MAP3K10 (ENSG00000130758), MAP3K9 (ENSG00000006432), MAP3K11 (ENSG00000173327)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.941 | Q17 | What gene does the drug Vs-5584 target? | The drug Vs-5584 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 9 genes: PIK3CB, PIK3R3, PIK3R5, PIK3CG, PIK3R2, PIK3R1, PIK3CA, MTOR and PIK3CD | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vs-5584%" OR LOWER(tradeNames_string) LIKE "%vs-5584%" OR LOWER(drugSynonyms_string) LIKE "%vs-5584%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4506', 'drugName': 'Vs-5584', 'tradeNames_string': '', 'drugSynonyms_string': 'VS-5584, Vs 5584, Vs-5584', 'linkedDiseasesDrug_string': 'Mesothelioma (EFO_0000588), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_4507', 'drugName': 'Vs-5584', 'tradeNames_string': '', 'drugSynonyms_string': 'VS-5584, Vs 5584, Vs-5584', 'linkedDiseasesDrug_string': 'Mesothelioma (EFO_0000588), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461), MTOR (ENSG00000198793)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.993 | Q17 | What gene does the drug Siponimod target? | The drug Siponimod targets the gene S1PR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%siponimod%" OR LOWER(tradeNames_string) LIKE "%siponimod%" OR LOWER(drugSynonyms_string) LIKE "%siponimod%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4451', 'drugName': 'Siponimod Fumarate', 'tradeNames_string': 'Mayzent', 'drugSynonyms_string': 'NVP-BAF312-AEA, Siponimod fumarate, Siponimod fumaric acid, Siponimod hemifumarate, Siponimod hemifumaric acid', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Chronic Progressive Multiple Sclerosis (EFO_0003840)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_265', 'drugName': 'Siponimod', 'tradeNames_string': '', 'drugSynonyms_string': 'BAF-312, BAF312, Baf312, NVP-BAF312-NX, Siponimod', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Chronic Progressive Multiple Sclerosis (EFO_0003840), Kidney Disease (EFO_0003086), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Polymyositis (EFO_0003063), Dermatomyositis (EFO_0000398), Immune System Disease (EFO_0000540), Secondary Progressive Multiple Sclerosis (EFO_0008522)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.868 | Q17 | What gene does the drug Ctce-9908 target? | The drug Ctce-9908 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CXCR4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ctce-9908%" OR LOWER(tradeNames_string) LIKE "%ctce-9908%" OR LOWER(drugSynonyms_string) LIKE "%ctce-9908%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_626', 'drugName': 'Ctce-9908', 'tradeNames_string': '', 'drugSynonyms_string': 'CTCE 9908, Ctce-9908', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CXCR4 (ENSG00000121966)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1951 | Q17 | What gene does the drug Mogamulizumab target? | The drug Mogamulizumab targets the gene CCR4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mogamulizumab%" OR LOWER(tradeNames_string) LIKE "%mogamulizumab%" OR LOWER(drugSynonyms_string) LIKE "%mogamulizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_879', 'drugName': 'Mogamulizumab', 'tradeNames_string': 'Poteligeo', 'drugSynonyms_string': 'AMG-761, KM-8761, KM8761, KW-0761, Mogamulizumab, Mogamulizumab (genetical recombination), Mogamulizumab kpkc, Mogamulizumab-kpkc', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Hepatocellular Carcinoma (EFO_0000182), Asthma (MONDO_0004979), Neoplasm (EFO_0000616), Tropical Spastic Paraparesis (EFO_0007527), Non-Small Cell Lung Carcinoma (EFO_0003060), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Mycosis Fungoides (EFO_1001051), Carcinoma (EFO_0000313), Cutaneous T-Cell Lymphoma (EFO_0002913), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)", 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CCR4 (ENSG00000183813)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.558 | Q17 | What gene does the drug Riviciclib target? | The drug Riviciclib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: CDK9, CDK4 and CDK1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%riviciclib%" OR LOWER(tradeNames_string) LIKE "%riviciclib%" OR LOWER(drugSynonyms_string) LIKE "%riviciclib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3342', 'drugName': 'Riviciclib', 'tradeNames_string': '', 'drugSynonyms_string': 'P 276-00 free base, P-276-00 free base, P276-00, Riviciclib', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK9 (ENSG00000136807), CDK1 (ENSG00000170312), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3343', 'drugName': 'Riviciclib', 'tradeNames_string': '', 'drugSynonyms_string': 'P 276-00 free base, P-276-00 free base, P276-00, Riviciclib', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK9 (ENSG00000136807), CDK1 (ENSG00000170312), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3344', 'drugName': 'Riviciclib', 'tradeNames_string': '', 'drugSynonyms_string': 'P 276-00 free base, P-276-00 free base, P276-00, Riviciclib', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK9 (ENSG00000136807), CDK1 (ENSG00000170312), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.433 | Q17 | What gene does the drug Darifenacin target? | The drug Darifenacin targets 2 genes: CHRM2 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%darifenacin%" OR LOWER(tradeNames_string) LIKE "%darifenacin%" OR LOWER(drugSynonyms_string) LIKE "%darifenacin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4015', 'drugName': 'Darifenacin', 'tradeNames_string': '', 'drugSynonyms_string': 'Darifenacin, Darifenacin extended release, Enablex, UK-88525', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Urinary Incontinence (HP_0000020), Polyuria (HP_0000103), Urgency Urinary Incontinence (EFO_0006865)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4014', 'drugName': 'Darifenacin', 'tradeNames_string': '', 'drugSynonyms_string': 'Darifenacin, Darifenacin extended release, Enablex, UK-88525', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Urinary Incontinence (HP_0000020), Polyuria (HP_0000103), Urgency Urinary Incontinence (EFO_0006865)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2521', 'drugName': 'Darifenacin Hydrobromide', 'tradeNames_string': 'Darifenacin hydrobromide, Emselex, Enablex', 'drugSynonyms_string': 'Darifenacin hbr, Darifenacin hydrobromide, UK-88525-04 (HYDROBROMIDE), Uk-88525-04 (hbr)', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Urgency Urinary Incontinence (EFO_0006865)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2520', 'drugName': 'Darifenacin Hydrobromide', 'tradeNames_string': 'Darifenacin hydrobromide, Emselex, Enablex', 'drugSynonyms_string': 'Darifenacin hbr, Darifenacin hydrobromide, UK-88525-04 (HYDROBROMIDE), Uk-88525-04 (hbr)', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Urgency Urinary Incontinence (EFO_0006865)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1777 | Q17 | What gene does the drug Vismodegib target? | The drug Vismodegib targets the gene SMO. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vismodegib%" OR LOWER(tradeNames_string) LIKE "%vismodegib%" OR LOWER(drugSynonyms_string) LIKE "%vismodegib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5550', 'drugName': 'Vismodegib', 'tradeNames_string': 'Erivedge', 'drugSynonyms_string': 'GDC-0449, NSC-747691, NSC-755986, Vismodegib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nevoid Basal Cell Carcinoma Syndrome (MONDO_0007187), Multiple Myeloma (EFO_0001378), Medulloblastoma (EFO_0002939), Central Nervous System Cancer (EFO_0000326), Idiopathic Pulmonary Fibrosis (EFO_0000768), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Mesenchymal Chondrosarcoma (EFO_1001041), Breast Carcinoma (EFO_0000305), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Myelofibrosis (MONDO_0044903), Acute Myeloid Leukemia (EFO_0000222), Basal Cell Carcinoma (EFO_0004193), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Skin Basal Cell Carcinoma (MONDO_0005341), Neoplasm (EFO_0000616), Meningioma (MONDO_0016642), Clear Cell Chondrosarcoma (MONDO_0003684), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1834 | Q17 | What gene does the drug Cilengitide target? | The drug Cilengitide is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: ITGB3, ITGB5 and ITGAV | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cilengitide%" OR LOWER(tradeNames_string) LIKE "%cilengitide%" OR LOWER(drugSynonyms_string) LIKE "%cilengitide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5584', 'drugName': 'Cilengitide', 'tradeNames_string': '', 'drugSynonyms_string': 'Cilengitide, EMD 121974, EMD-12192, EMD-121974', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Central Nervous System Cancer (EFO_0000326), Myelodysplastic Syndrome (EFO_0000198), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Male Breast Carcinoma (EFO_0006861), Cerebral Astrocytoma (MONDO_0021633), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Chronic Myeloproliferative Disorder (EFO_0002428), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Squamous Cell Carcinoma (EFO_0000707), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGB3 (ENSG00000259207), ITGAV (ENSG00000138448), ITGB5 (ENSG00000082781)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5585', 'drugName': 'Cilengitide', 'tradeNames_string': '', 'drugSynonyms_string': 'Cilengitide, EMD 121974, EMD-12192, EMD-121974', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Central Nervous System Cancer (EFO_0000326), Myelodysplastic Syndrome (EFO_0000198), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Male Breast Carcinoma (EFO_0006861), Cerebral Astrocytoma (MONDO_0021633), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Chronic Myeloproliferative Disorder (EFO_0002428), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Squamous Cell Carcinoma (EFO_0000707), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGB3 (ENSG00000259207), ITGAV (ENSG00000138448), ITGB5 (ENSG00000082781)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1977 | Q17 | What gene does the drug Isoxsuprine Hydrochloride target? | The drug Isoxsuprine Hydrochloride targets 4 genes: ADRA1D, ADRA1B, ADRA1A and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%isoxsuprine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%isoxsuprine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%isoxsuprine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2488', 'drugName': 'Isoxsuprine Hydrochloride', 'tradeNames_string': 'Defencin, Duvadilan, Duvadilan ret, Vasodilan', 'drugSynonyms_string': 'Dilavase, Duviculine, Isoxsuprine hcl, Isoxsuprine hydrochloride, NSC-757067, Navilox, Suprilent, Vadosilan, Vasotran', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2489', 'drugName': 'Isoxsuprine Hydrochloride', 'tradeNames_string': 'Defencin, Duvadilan, Duvadilan ret, Vasodilan', 'drugSynonyms_string': 'Dilavase, Duviculine, Isoxsuprine hcl, Isoxsuprine hydrochloride, NSC-757067, Navilox, Suprilent, Vadosilan, Vasotran', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1506 | Q17 | What gene does the drug Rabeprazole Sodium target? | The drug Rabeprazole Sodium targets 2 genes: ATP4B and ATP4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rabeprazole sodium%" OR LOWER(tradeNames_string) LIKE "%rabeprazole sodium%" OR LOWER(drugSynonyms_string) LIKE "%rabeprazole sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5144', 'drugName': 'Rabeprazole Sodium', 'tradeNames_string': 'Aciphex, Aciphex sprinkle, Pariet, Rabeprazole sodium', 'drugSynonyms_string': 'E-3810, E-3810 SODIUM, Idiazole, LY-307640, LY-307640 SODIUM, LY307640 SODIUM, NSC-759270, Rabeprazole na, Rabeprazole sodium, Rabeprazole sodium salt, Sodium rabeprazole', 'linkedDiseasesDrug_string': 'Laryngopharyngeal Reflux (EFO_1001355), Duodenal Ulcer (EFO_0004607), Zollinger-Ellison Syndrome (EFO_0007549), Cerebrovascular Disorder (EFO_0003763), Peptic Esophagitis (EFO_1001095), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1622 | Q17 | What gene does the drug Prednisolone target? | The drug Prednisolone targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prednisolone%" OR LOWER(tradeNames_string) LIKE "%prednisolone%" OR LOWER(drugSynonyms_string) LIKE "%prednisolone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_535', 'drugName': 'Dexamethasone', 'tradeNames_string': 'Aeroseb-dex, Dalalone, Decaderm, Decadron, Decadron-75, Decaspray, Dexacortisyl, Dexafree, Dexamethasone, Dexamethasone intensol, Dexone, Dexone 0.5, Dexone 0.75, Dexone 1.5, Dexone 4, Dexsol, Dextenza, Dexycu kit, Dropodex, Gppe ear spy, Hemady, Hexadrol, Kortico Injection, Martapan, Maxidex, Maxitrol, Oradexon, Otomize, Ozurdex, Sofradex, Spersadex comp, Tobradex', 'drugSynonyms_string': 'Decadron-LA, Dexacen-4, Dexacort, Dexair, Dexamethasone, Dexamethasone metasulfobenzoate sodium, Dexamethasone palmitate, Dexamethasone valerate, Dexycu, Fluormethylprednisolone, ISV-305, Mymethasone, NSC-34521, Neodecadron, OTO-104', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Psoriasis (EFO_0000676), Intracranial Subdural Hematoma (EFO_1001801), Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Ankylosing Spondylitis (EFO_0003898), Nervous System Disease (EFO_0000618), Migraine Disorder (MONDO_0005277), Wet Macular Degeneration (EFO_0004683), Hemophagocytic Syndrome (MONDO_0015540), Refractory Anemia (EFO_0003802), Allergic Rhinitis (EFO_0005854), Pregnancy (EFO_0002950), Eosinophilic Pneumonia (EFO_0007257), Iridocyclitis (HP_0001094), Lymphoid Neoplasm (EFO_0001642), Anaphylaxis (MONDO_0100053), Sciatica (HP_0011868), Acute Myelomonocytic Leukemia (EFO_0000223), Pemphigus Vulgaris (EFO_0004719), Seasonal Allergic Rhinitis (EFO_0003956), Dermatitis Herpetiformis (EFO_1000684), Congenital Adrenal Hyperplasia (MONDO_0018479), Atopic Eczema (EFO_0000274), Hypertension (EFO_0000537), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Hearing Loss (EFO_0004238), Knee Injury (EFO_0009507), Aplastic Anemia (HP_0001915), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Keratitis (EFO_0009449), Plantar Fasciitis (EFO_1001909), Retinopathy Of Prematurity (EFO_1001158), Primary Adrenal Insufficiency (MONDO_0015128), Optic Neuritis (EFO_0007405), Neck Pain (HP_0030833), Viral Pneumonia (EFO_0007541), Anemia (Phenotype) (EFO_0004272), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Sickle Cell Anemia (MONDO_0011382), Endocrine Neoplasm (EFO_0003769), Castleman Disease (MONDO_0015564), Acute Erythroleukemia (EFO_0000218), Hemolytic Anemia (EFO_0005558), T-Lymphoblastic Lymphoma (MONDO_0044917), Liver Cancer (MONDO_0002691), Choroiditis (MONDO_0001280), Gout (EFO_0004274), Congenital Heart Disease (EFO_0005207), Iritis (EFO_1000997), Intracranial Hypertension (EFO_1000992), Follicular Lymphoma (MONDO_0018906), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Adrenal Gland Hyperfunction (EFO_1000797), Classic Hodgkin Lymphoma (MONDO_0009348), Colorectal Adenocarcinoma (EFO_0000365), Adrenocortical Insufficiency (EFO_0009491), Kidney Disease (EFO_0003086), Dysphagia (HP_0002015), Myocarditis (EFO_0009609), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Nausea (HP_0002018), Al Amyloidosis (MONDO_0019438), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Mastoiditis (HP_0000265), Pain (EFO_0003843), Nephrosis (MONDO_0002331), Sympathetic Ophthalmia (EFO_1001205), Anaplastic Large Cell Lymphoma (EFO_0003032), Pulmonary Tuberculosis (EFO_1000049), Pure Red-Cell Aplasia (MONDO_0001705), Squamous Cell Lung Carcinoma (EFO_0000708), Male Reproductive Organ Cancer (EFO_0007355), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Breast Carcinoma In Situ (MONDO_0004658), Prostate Carcinoma (EFO_0001663), Meningitis (MONDO_0021108), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728), Hepatocellular Carcinoma (EFO_0000182), Congestive Heart Failure (EFO_0000373), Headache (HP_0002315), Mantle Cell Lymphoma (EFO_1001469), Myxoid Liposarcoma (EFO_0000613), Cerebral Toxoplasmosis (EFO_0007200), Cataract (MONDO_0005129), Diabetic Retinopathy (EFO_0003770), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Acute Respiratory Distress Syndrome (EFO_1000637), Peptic Ulcer (HP_0004398), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Allergic Conjunctivitis (EFO_0007141), Vitiligo (EFO_0004208), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Small Cell Lung Carcinoma (EFO_0000702), Intestinal Obstruction (MONDO_0004565), Proliferative Vitreoretinopathy (EFO_1001129), Hemorrhoid (EFO_0009552), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Bacterial Vaginosis (EFO_0003932), Dyspnea (HP_0002094), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Atrioventricular Block (MONDO_0000465), Osteoarthritis (MONDO_0005178), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Non-Small Cell Lung Carcinoma (EFO_0003060), Radiculopathy (MONDO_0002959), Vomiting (HP_0002013), Posterior Uveitis (EFO_1001119), Neuralgia (EFO_0009430), Sinus Histiocytosis With Massive Lymphadenopathy (MONDO_0006412), Acute Monocytic Leukemia (EFO_0000221), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Dermatitis (MONDO_0002406), Asymptomatic Myeloma (EFO_0003073), Retinal Vein Occlusion (EFO_1001157), Hellp Syndrome (EFO_0007297), Oral Lichen Planus (EFO_0008517), Chorioretinitis (HP_0012424), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Langerhans Cell Histiocytosis (EFO_1000318), Eye Disease (EFO_0003966), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Plasmacytoma (EFO_0006738), Glomerulonephritis (MONDO_0002462), Urothelial Carcinoma (EFO_0008528), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Otitis Media (EFO_0004992), Meniere Disease (EFO_0006862), Intrahepatic Cholangiocarcinoma (EFO_1001961), Glaucoma (MONDO_0005041), Focal Segmental Glomerulosclerosis (EFO_0004236), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Bronchiolitis (HP_0011950), Psoriasis Vulgaris (EFO_1001494), Primary Progressive Multiple Sclerosis (EFO_0008520), Deafness (EFO_0001063), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Hyperuricemia (EFO_0009104), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Pelvic Organ Prolapse (EFO_0004710), Blepharitis (EFO_0009536), Rotator Cuff Tear (EFO_1001250), Juvenile Idiopathic Arthritis (EFO_0002609), Bursitis (MONDO_0002471), Psoriatic Arthritis (EFO_0003778), Osteoarthritis, Knee (EFO_0004616), Frozen Shoulder (EFO_1000941), Epiphora (HP_0009926), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Female Reproductive System Neoplasm (MONDO_0021148), Lymphoma (EFO_0000574), Acne (EFO_0003894), Mycosis Fungoides (EFO_1001051), Tenosynovitis (EFO_1001435), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Hypercalcemia (HP_0003072), Cholangiocarcinoma (EFO_0005221), Exfoliative Dermatitis (EFO_0009456), Corneal Edema (EFO_1000879), Acute Megakaryoblastic Leukaemia (EFO_0003025), Pancreatic Carcinoma (EFO_0002618), Anterior Uveitis (EFO_1000811), Contact Dermatitis (EFO_0005319), Premature Birth (EFO_0003917), Intermediate Uveitis (EFO_1000986), Neoplasm Of Mature B-Cells (EFO_0000096), Rhinitis, Allergic, Perennial (EFO_1001417), Brain Edema (EFO_1000845), Leptospirosis (EFO_0007344), Mesothelioma (EFO_0000588), Urinary Tract Infection (EFO_0003103), Waldenstrom Macroglobulinemia (EFO_0009441), Allergic Disease (MONDO_0005271), Erythema Multiforme (EFO_1000694), Alcohol Dependence (MONDO_0007079), Leptomeningeal Metastasis (EFO_1001012), Age-Related Macular Degeneration (EFO_0001365), Sarcoidosis (MONDO_0019338), Strabismus (HP_0000486), Ophthalmic Herpes Zoster (EFO_0007403), Leiomyoma (MONDO_0001572), Neoplasm (EFO_0000616), Pemphigus (EFO_1000749), Nausea And Vomiting (HP_0002017), Urinary Bladder Cancer (MONDO_0001187), Chronic Pain (HP_0012532), Xerostomia (EFO_0009869), Tuberculosis (MONDO_0018076), Sarcoma (EFO_0000691), Seborrheic Dermatitis (EFO_1000764), Primary Systemic Amyloidosis (MONDO_0017816), Pulmonary Fibrosis (EFO_0009448), Aortic Coarctation (EFO_1001267), Amyloidosis (EFO_1001875), Lateral Epicondylitis (EFO_1001896), Rheumatic Disease (EFO_0005755), Oral Cavity Cancer (EFO_0005570), Pneumonia (EFO_0003106), Cryptococcal Meningitis (EFO_0007228), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Otitis Externa (EFO_0009560), Specific Language Disorder (MONDO_0016226), Post Operative Nausea And Vomiting (EFO_0004888), Systemic Lupus Erythematosus (MONDO_0007915), Dry Eye Syndrome (EFO_1000906), Injury (EFO_0000546), Burkitts Lymphoma (EFO_0000309), Appendicitis (EFO_0007149), Stevens-Johnson Syndrome (EFO_0004276), Ulcerative Colitis (EFO_0000729), Endometrial Cancer (MONDO_0011962), Plasma Cell Leukemia (EFO_0006475), Malaria (EFO_0001068), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Nephrotic Syndrome (EFO_0004255), Radius Fracture (EFO_0003957), Henoch-Schoenlein Purpura (EFO_1000965), Scleritis (MONDO_0001718), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Herpetic Encephalitis (Orphanet_1930), Breast Carcinoma (EFO_0000305), Tooth Disease (EFO_1001216), Eye Inflammation (EFO_0005752), Chronic Myelomonocytic Leukemia (EFO_1001779), Viral Conjunctivitis (EFO_0008571), Thrombocytopenia (HP_0001873), Radiation-Induced Nausea And Vomiting (EFO_0006912), Respiratory System Disease (EFO_0000684), Refractory Anemia With Excess Blasts (EFO_0003811), Sepsis (HP_0100806), Lichen Planus (EFO_1000726), Synovitis (EFO_0008997), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Graves Disease (EFO_0004237), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Poems Syndrome (EFO_1001115), Back Pain (HP_0003418), Subarachnoid Hemorrhage (EFO_0000713), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Recurrent Tonsillitis (HP_0011110), Cystoid Macular Edema (MONDO_0007935), Subacute Thyroiditis (EFO_1001194), Cysticercosis (EFO_0007231), Meningeal Tuberculosis (EFO_1000039), Ovarian Neoplasm (EFO_0003893), Nasal Congestion (HP_0001742), Macular Retinal Edema (MONDO_0003005), Lymphoid Leukemia (EFO_0004289), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), T-Cell Leukemia (EFO_0005592), Nasopharyngeal Neoplasm (EFO_0004252), Trichinosis (EFO_0007520), Sensorineural Hearing Loss (EFO_1001176), Melanoma (EFO_0000756), Fatigue (HP_0012378), Cirrhosis Of Liver (EFO_0001422), Bronchopulmonary Dysplasia (MONDO_0019091), Severe Acute Respiratory Syndrome (EFO_0000694), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 1958, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_670', 'drugName': 'Methylprednisolone Hemisuccinate', 'tradeNames_string': '', 'drugSynonyms_string': 'Methylprednisolone hemisuccinate, Methylprednisolone succinate', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Pneumonia (EFO_0003106), Multiple Sclerosis (MONDO_0005301), Drug-Induced Liver Injury (EFO_0004228), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Graft Versus Host Disease (MONDO_0013730), Glomerulonephritis (MONDO_0002462), Iga Glomerulonephritis (EFO_0004194), Systemic Lupus Erythematosus (MONDO_0007915), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Endocrine System Disease (EFO_0001379), Deafness (EFO_0001063), Bacterial Pneumonia (EFO_1001272), Juvenile Idiopathic Arthritis (EFO_0002609), Bursitis (MONDO_0002471), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Psoriatic Arthritis (EFO_0003778), Vestibular Neuronitis (EFO_0007537), Acute Myeloid Leukemia (EFO_0000222), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Acne (EFO_0003894), Acute Graft Vs. Host Disease (EFO_0004599), Epilepsy (EFO_0000474), Immune System Disease (EFO_0000540), Secondary Progressive Multiple Sclerosis (EFO_0008522), Asthma (MONDO_0004979), Chronic Progressive Multiple Sclerosis (EFO_0003840), Inflammation (MP_0001845), Anemia (MONDO_0002280), Rheumatoid Arthritis (EFO_0000685), Osteoarthritis (MONDO_0005178), Leukemia (EFO_0000565), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Japanese Encephalitis (EFO_0007332), Posterior Uveitis (EFO_1001119), Severe Acute Respiratory Syndrome (EFO_0000694), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2586', 'drugName': 'Prednisolone Sodium Phosphate', 'tradeNames_string': 'Codelsol, Cortisate, Hydeltrasol, Inflamase, Inflamase forte, Inflamase mild, Metreton, Orapred, Orapred odt, Pediapred, Predair, Predair forte, Prednisolone sodium phosphate, Predsol, Predsol-n', 'drugSynonyms_string': 'NSC-759187, Prednisolone 21-disodium phosphate, Prednisolone sodium phosphate, Prednisoloni natrii phosphas', 'linkedDiseasesDrug_string': 'Uveitis (EFO_1001231), Acanthamoeba Keratitis (EFO_0007126), Allergic Conjunctivitis (EFO_0007141), Asthma (MONDO_0004979), Nephrotic Syndrome (EFO_0004255), Idiopathic Pulmonary Fibrosis (EFO_0000768), Leukemia (EFO_0000565), Multiple Sclerosis (MONDO_0005301), Chronic Obstructive Pulmonary Disease (EFO_0000341), Otitis Media With Effusion (EFO_0007415), Anemia (MONDO_0002280), Inflammation (MP_0001845), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Pulmonary Fibrosis (EFO_0009448), Allergic Rhinitis (EFO_0005854), Uremia (EFO_1001226), Corneal Scarring (HP_0000559)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5936', 'drugName': 'Prednisolone Phosphoric Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'Prednisolone phosphate, Prednisolone phosphoric acid', 'linkedDiseasesDrug_string': 'Uveitis (EFO_1001231), Acanthamoeba Keratitis (EFO_0007126), Allergic Conjunctivitis (EFO_0007141), Asthma (MONDO_0004979), Nephrotic Syndrome (EFO_0004255), Idiopathic Pulmonary Fibrosis (EFO_0000768), Leukemia (EFO_0000565), Multiple Sclerosis (MONDO_0005301), Chronic Obstructive Pulmonary Disease (EFO_0000341), Otitis Media With Effusion (EFO_0007415), Anemia (MONDO_0002280), Inflammation (MP_0001845), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Pulmonary Fibrosis (EFO_0009448), Allergic Rhinitis (EFO_0005854), Uremia (EFO_1001226), Herpes Simplex Virus Keratitis (EFO_0007308), Corneal Scarring (HP_0000559)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5705', 'drugName': 'Methylprednisolone Sodium Succinate', 'tradeNames_string': 'A-methapred, Methylprednisolone, Methylprednisolone sodium succinate, Min-i-mix, Solu-medrol, Solu-medrone, Urbasone', 'drugSynonyms_string': 'Methylprednisolone 21-succinate sodium salt, Methylprednisolone sodium succinate, NSC-48989', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Pneumonia (EFO_0003106), Multiple Sclerosis (MONDO_0005301), Drug-Induced Liver Injury (EFO_0004228), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Graft Versus Host Disease (MONDO_0013730), Glomerulonephritis (MONDO_0002462), Iga Glomerulonephritis (EFO_0004194), Systemic Lupus Erythematosus (MONDO_0007915), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Endocrine System Disease (EFO_0001379), Deafness (EFO_0001063), Bacterial Pneumonia (EFO_1001272), Juvenile Idiopathic Arthritis (EFO_0002609), Bursitis (MONDO_0002471), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Psoriatic Arthritis (EFO_0003778), Vestibular Neuronitis (EFO_0007537), Acute Myeloid Leukemia (EFO_0000222), Acne (EFO_0003894), Acute Graft Vs. Host Disease (EFO_0004599), Epilepsy (EFO_0000474), Immune System Disease (EFO_0000540), Secondary Progressive Multiple Sclerosis (EFO_0008522), Asthma (MONDO_0004979), Chronic Progressive Multiple Sclerosis (EFO_0003840), Anemia (MONDO_0002280), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Osteoarthritis (MONDO_0005178), Leukemia (EFO_0000565), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Japanese Encephalitis (EFO_0007332), Posterior Uveitis (EFO_1001119), Severe Acute Respiratory Syndrome (EFO_0000694), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4703', 'drugName': 'Methylprednisolone', 'tradeNames_string': 'Medrol, Medrone, Methylprednisolone', 'drugSynonyms_string': 'J3.872E, Methylprednisolone, NSC-19987, U-67,590A', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Intracranial Subdural Hematoma (EFO_1001801), Ankylosing Spondylitis (EFO_0003898), Hemophagocytic Syndrome (MONDO_0015540), Iga Glomerulonephritis (EFO_0004194), Spinal Cord Injury (EFO_1001919), Lymphoid Neoplasm (EFO_0001642), Graves Ophthalmopathy (EFO_1001466), Ischemic Stroke (HP_0002140), Atopic Eczema (EFO_0000274), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Aplastic Anemia (HP_0001915), Granulomatosis With Polyangiitis (EFO_0005297), Plantar Fasciitis (EFO_1001909), Nasal Cavity Polyp (EFO_1000391), Optic Neuritis (EFO_0007405), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Chronic Progressive Multiple Sclerosis (EFO_0003840), Heart Disease (EFO_0003777), Leukemia (EFO_0000565), Lymphoma, Aids-Related (EFO_1001365), Classic Hodgkin Lymphoma (MONDO_0009348), Dysphagia (HP_0002015), Kidney Disease (EFO_0003086), Myocarditis (EFO_0009609), Atherosclerosis (EFO_0003914), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Lupus Nephritis (EFO_0005761), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Friedreich Ataxia (MONDO_0100339), Chronic Lymphocytic Leukemia (EFO_0000095), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Juvenile Dermatomyositis (EFO_0000557), Neuromyelitis Optica (EFO_0004256), Anaplastic Large Cell Lymphoma (EFO_0003032), Familial Lipoprotein Lipase Deficiency (MONDO_0009387), Myelodysplastic Syndrome (EFO_0000198), Aging (GO_0007568), Coronavirus Infectious Disease (EFO_0007224), Edema (EFO_0009373), Gangliosidosis (MONDO_0017719), Acute Lymphoblastic Leukemia (EFO_0000220), Vestibular Neuronitis (EFO_0007537), Sudden Cardiac Arrest (EFO_0004278), Acute Respiratory Distress Syndrome (EFO_1000637), Diffuse Large B-Cell Lymphoma (EFO_0000403), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), Optic Nerve Disorder (MONDO_0002135), Chronic Kidney Disease (EFO_0003884), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Frontotemporal Dementia (MONDO_0017276), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Myeloproliferative Disorder (EFO_0004251), Non-Small Cell Lung Carcinoma (EFO_0003060), Radiculopathy (MONDO_0002959), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Spondyloarthropathy (EFO_0000706), Carpal Tunnel Syndrome (EFO_0004143), Macrophage Activation Syndrome (EFO_1001806), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Bell'S Palsy (EFO_0007167), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Shoulder Pain (HP_0030834), Meniere Disease (EFO_0006862), Ovarian Cancer (MONDO_0008170), Primary Progressive Multiple Sclerosis (EFO_0008520), Hepatitis, Alcoholic (EFO_1001345), Hyperuricemia (EFO_0009104), Breast Cancer (MONDO_0007254), Psoriatic Arthritis (EFO_0003778), Lymphoma (EFO_0000574), Frozen Shoulder (EFO_1000941), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Acne (EFO_0003894), Tenosynovitis (EFO_1001435), Microscopic Polyangiitis (EFO_1000784), 22Q11.2 Deletion Syndrome (MONDO_0018923), Chronic Obstructive Pulmonary Disease (EFO_0000341), Urinary Tract Infection (EFO_0003103), Polyp (EFO_0000662), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Hantavirus Infectious Disease (EFO_0007295), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826), Lymphoproliferative Syndrome (MONDO_0016537), Pneumonia (EFO_0003106), Developmental And Epileptic Encephalopathy (MONDO_0100062), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Abdominal Pain (HP_0002027), Specific Language Disorder (MONDO_0016226), Systemic Lupus Erythematosus (MONDO_0007915), Appendicitis (EFO_0007149), Myasthenia Gravis (EFO_0004991), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Gaucher Disease (MONDO_0018150), Burkitts Lymphoma (EFO_0000309), Ulcerative Colitis (EFO_0000729), Gaucher Disease Type 2 (Orphanet_77260), Anterior Ischemic Optic Neuropathy (EFO_1000809), Henoch-Schoenlein Purpura (EFO_1000965), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Stiff-Person Syndrome (EFO_0007498), Parkinson Disease (MONDO_0005180), Acute Graft Vs. Host Disease (EFO_0004599), Drug-Induced Hepatitis (EFO_1000905), Immune System Disease (EFO_0000540), Myopathy (EFO_0004145), Membranous Glomerulonephritis (EFO_0004254), Cardiac Arrest (EFO_0009492), Thrombocytopenia (HP_0001873), Respiratory System Disease (EFO_0000684), Language Disorder (MONDO_0004750), Lymphoblastic Lymphoma (MONDO_0000873), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Igg4-Related Disease (MONDO_0017287), Mucocutaneous Lymph Node Syndrome (EFO_0004246), Fallopian Tube Cancer (MONDO_0002158), Cognitive Impairment (HP_0100543), Amyotrophic Lateral Sclerosis (MONDO_0004976), Melanoma (EFO_0000756), Noise-Induced Hearing Loss (EFO_1001254), Pneumocystosis (EFO_0007448), Bronchopulmonary Dysplasia (MONDO_0019091), Severe Acute Respiratory Syndrome (EFO_0000694)", 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5344', 'drugName': 'Prednisolone Acetate', 'tradeNames_string': 'Econopred, Flo-pred, Meticortelone, Omnipred, Pred forte, Pred fte, Pred mild, Prednisolone acetate, Sterane, Ultracortenol', 'drugSynonyms_string': 'NSC-10966, Prednisolone 21-acetate, Prednisolone Acetate, Prednisolone acetate, Prednisoloni acetas', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Anterior Uveitis (EFO_1000811), Uveitis (EFO_1001231), Iritis (EFO_1000997), Retinal Vein Occlusion (EFO_1001157), Sciatica (HP_0011868), Cataract (MONDO_0005129), Multiple Sclerosis (MONDO_0005301), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Corneal Scarring (HP_0000559), Inflammation (MP_0001845), Anemia (MONDO_0002280), Low Back Pain (HP_0003419), Nasal Congestion (HP_0001742), Eye Infection (EFO_1001888), Macular Retinal Edema (MONDO_0003005)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1842', 'drugName': 'Prednisolone', 'tradeNames_string': 'Cortalone, Dekotil, Delta-cortef, Deltacortril, Deltalone, Dilacort, Fernisolone-p, Hydeltra, Meti-derm, Meticortelone, Pevanti, Precortisyl, Precortisyl fte, Prednisolone, Prelone, Scheriproct, Servisone, Sterane', 'drugSynonyms_string': 'Desowen, Hydeltra-Tba, Meticortelone, NSC-9120, NSC-9900, Neo-Delta-Cortef, Poly-Pred, Pred-G, Prednisolone, Servisone, Tridesilon, Verdeso', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Allergic Bronchopulmonary Aspergillosis (EFO_0007140), Ankylosing Spondylitis (EFO_0003898), Hemophagocytic Syndrome (MONDO_0015540), Iga Glomerulonephritis (EFO_0004194), Allergic Rhinitis (EFO_0005854), Eosinophilic Pneumonia (EFO_0007257), Iridocyclitis (HP_0001094), Temporal Arteritis (EFO_1001209), Ischemic Stroke (HP_0002140), Dermatitis Herpetiformis (EFO_1000684), Atopic Eczema (EFO_0000274), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Hypereosinophilic Syndrome (EFO_1001467), Aplastic Anemia (HP_0001915), Granulomatosis With Polyangiitis (EFO_0005297), Keratitis (EFO_0009449), Primary Adrenal Insufficiency (MONDO_0015128), Optic Neuritis (EFO_0007405), Biliary Atresia (MONDO_0008867), Hemangioma (EFO_1000635), Habitual Abortion (EFO_1000954), Ocular Hypertension (EFO_1001069), Hemolytic Anemia (EFO_0005558), Choroiditis (MONDO_0001280), Gout (EFO_0004274), Orbital Plasma Cell Granuloma (EFO_1001077), Iritis (EFO_1000997), Follicular Lymphoma (MONDO_0018906), Churg-Strauss Syndrome (EFO_0007208), Leukemia (EFO_0000565), Pericarditis (EFO_0007427), Adrenocortical Insufficiency (EFO_0009491), Kidney Disease (EFO_0003086), Lipoma (EFO_0000759), Myocarditis (EFO_0009609), Schizophrenia (MONDO_0005090), Lupus Nephritis (EFO_0005761), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Multiple Sclerosis (MONDO_0005301), Sympathetic Ophthalmia (EFO_1001205), Pure Red-Cell Aplasia (MONDO_0001705), Anaplastic Large Cell Lymphoma (EFO_0003032), Pulmonary Tuberculosis (EFO_1000049), Familial Lipoprotein Lipase Deficiency (MONDO_0009387), Prostate Carcinoma (EFO_0001663), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728), Uveitis (EFO_1001231), Hepatocellular Carcinoma (EFO_0000182), Headache (HP_0002315), Cataract (MONDO_0005129), Acute Lymphoblastic Leukemia (EFO_0000220), Vestibular Neuronitis (EFO_0007537), Acute Myeloid Leukemia (EFO_0000222), Polymyalgia Rheumatica (EFO_0008518), Peptic Ulcer (HP_0004398), Dermatomyositis (EFO_0000398), Diffuse Large B-Cell Lymphoma (EFO_0000403), Allergic Conjunctivitis (EFO_0007141), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), West Syndrome (MONDO_0018097), Hemorrhoid (EFO_0009552), Duchenne Muscular Dystrophy (MONDO_0010679), Anemia, Hemolytic, Autoimmune (EFO_1001264), Hodgkins Lymphoma (EFO_0000183), Epicondylitis (EFO_1001887), Chronic Kidney Disease (EFO_0003884), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Hiv Infection (EFO_0000764), Pulpitis (EFO_1001139), Osteoarthritis (MONDO_0005178), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Posterior Uveitis (EFO_1001119), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Chorioretinitis (HP_0012424), Mucous Membrane Pemphigoid (EFO_1000680), Open-Angle Glaucoma (EFO_0004190), Glomerulonephritis (MONDO_0002462), Glaucoma (MONDO_0005041), Idiopathic Pulmonary Fibrosis (EFO_0000768), Focal Segmental Glomerulosclerosis (EFO_0004236), Leprosy (EFO_0001054), Hepatitis, Alcoholic (EFO_1001345), Breast Cancer (MONDO_0007254), Juvenile Idiopathic Arthritis (EFO_0002609), Aphthous Ulcer (EFO_0003938), Psoriatic Arthritis (EFO_0003778), Lymphoma (EFO_0000574), Frozen Shoulder (EFO_1000941), Mycosis Fungoides (EFO_1001051), Tenosynovitis (EFO_1001435), Hypercalcemia (HP_0003072), Exfoliative Dermatitis (EFO_0009456), Microscopic Polyangiitis (EFO_1000784), Contact Dermatitis (EFO_0005319), Neoplasm Of Mature B-Cells (EFO_0000096), Infertility (EFO_0000545), Chronic Obstructive Pulmonary Disease (EFO_0000341), Allergic Disease (MONDO_0005271), Erythema Multiforme (EFO_1000694), Age-Related Macular Degeneration (EFO_0001365), Eczema (HP_0000964), Sarcoidosis (MONDO_0019338), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Croup (EFO_0007227), Pemphigus (EFO_1000749), Ophthalmic Herpes Zoster (EFO_0007403), Metastatic Prostate Cancer (EFO_0000196), Seborrheic Dermatitis (EFO_1000764), Type 2 Diabetes Mellitus (MONDO_0005148), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826), Lateral Epicondylitis (EFO_1001896), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Systemic Lupus Erythematosus (MONDO_0007915), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Celiac Disease (EFO_0001060), Ulcerative Colitis (EFO_0000729), Prostate Adenocarcinoma (EFO_0000673), Nephrotic Syndrome (EFO_0004255), Familial Atrioventricular Septal Defect (MONDO_0020290), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Eye Inflammation (EFO_0005752), Membranous Glomerulonephritis (EFO_0004254), Thrombocytopenia (HP_0001873), Language Disorder (MONDO_0004750), Lichen Planus (EFO_1000726), Synovitis (EFO_0008997), Graves Disease (EFO_0004237), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Inflammation (MP_0001845), Extrinsic Allergic Alveolitis (EFO_1001321), Nasal Congestion (HP_0001742), Rheumatoid Arthritis (EFO_0000685), Subacute Thyroiditis (EFO_1001194), Systemic Scleroderma (EFO_0000717), Meningeal Tuberculosis (EFO_1000039), Eye Infection (EFO_1001888), Mucocutaneous Lymph Node Syndrome (EFO_0004246), Trichinosis (EFO_0007520), Colitis (EFO_0003872), Melanoma (EFO_0000756)", 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1579', 'drugName': 'Fluprednisolone', 'tradeNames_string': 'Alphadrol', 'drugSynonyms_string': 'Fluprednisolone, NSC-47439, U-7800', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_675', 'drugName': 'Methylprednisolone Acetate', 'tradeNames_string': 'Depmedalone, Depo-medrol, Depo-medrone, M-predrol, Medrol, Medrol acetate, Methylprednisolone acetate, Neo-medrone', 'drugSynonyms_string': 'Methyl prednisolone acetate, Methylprednisolone 21-acetate, Methylprednisolone acetate, NSC-48985', 'linkedDiseasesDrug_string': 'Lateral Epicondylitis (EFO_1001896), Pain (EFO_0003843), Nephrotic Syndrome (EFO_0004255), Uveitis (EFO_1001231), Neuropathic Pain (EFO_0005762), Frozen Shoulder (EFO_1000941), Lymphoma (EFO_0000574), Optic Neuritis (EFO_0007405), Asthma (MONDO_0004979), Fungal Infectious Disease (MONDO_0002041), Brain Neoplasm (EFO_0003833), Anemia (MONDO_0002280), Rheumatoid Arthritis (EFO_0000685), Gout (EFO_0004274), Osteoarthritis (MONDO_0005178), Leukemia (EFO_0000565), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Shoulder Impingement Syndrome (EFO_1001178), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2041', 'drugName': 'Triamcinolone', 'tradeNames_string': 'Aristocort, Aristocort A, Delphicort, Kenacort, Kenalog, Triamcinolone, Volon', 'drugSynonyms_string': 'Fluoxiprednisolone, NSC-13397, Triamcinolone', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Retinal Vein Occlusion (EFO_1001157), Oral Lichen Planus (EFO_0008517), Pain (EFO_0003843), Wet Macular Degeneration (EFO_0004683), Abdominal Pain (HP_0002027), Allergic Rhinitis (EFO_0005854), Shoulder Pain (HP_0030834), Anterior Ischemic Optic Neuropathy (EFO_1000809), Rotator Cuff Tear (EFO_1001250), Acneiform Dermatitis (EFO_1000662), Eye Inflammation (EFO_0005752), Atopic Eczema (EFO_0000274), Osteoarthritis, Knee (EFO_0004616), Neuropathic Pain (EFO_0005762), Freckles (EFO_0003963), Diabetic Retinopathy (EFO_0003770), Chronic Pancreatitis (EFO_0000342), Corneal Edema (EFO_1000879), Nasal Cavity Polyp (EFO_1000391), Keloid (EFO_0004212), Sinusitis (EFO_0007486), Vitiligo (EFO_0004208), Alopecia Areata (EFO_0004192), Osteoarthritis, Hip (EFO_1000786), Rhinitis, Allergic, Perennial (EFO_1001417), Hemorrhoid (EFO_0009552), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Nasal Congestion (HP_0001742), Age-Related Macular Degeneration (EFO_0001365), Macular Retinal Edema (MONDO_0003005), Orbital Plasma Cell Granuloma (EFO_1001077), Osteoarthritis (MONDO_0005178), Radiculopathy (MONDO_0002959), Melanoma (EFO_0000756), Vascular Disease (EFO_0004264), Skin Disease (EFO_0000701)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6303', 'drugName': 'Prednisolone Tebutate', 'tradeNames_string': 'Hydeltra-tba, Prednisolone tebutate', 'drugSynonyms_string': 'Anhydrous prednisolone tebutate, Prednisolone 21-tert-butylacetate, Prednisolone butylacetate, Prednisolone tebutate', 'linkedDiseasesDrug_string': 'Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Nasal Congestion (HP_0001742)', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.404 | Q17 | What gene does the drug Valdecoxib target? | The drug Valdecoxib targets the gene PTGS2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%valdecoxib%" OR LOWER(tradeNames_string) LIKE "%valdecoxib%" OR LOWER(drugSynonyms_string) LIKE "%valdecoxib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5955', 'drugName': 'Valdecoxib', 'tradeNames_string': 'Bextra', 'drugSynonyms_string': 'NSC-759846, SC-65872, Valdecoxib, Valdyn', 'linkedDiseasesDrug_string': 'Pancreatitis (EFO_0000278), Pharyngitis (MONDO_0002258), Osteoarthritis (MONDO_0005178), Rheumatic Disease (EFO_0005755), Pain (EFO_0003843), Osteoarthritis, Knee (EFO_0004616)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1791 | Q17 | What gene does the drug Pinacidil target? | The drug Pinacidil targets 2 genes: KCNJ11 and ABCC9. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pinacidil%" OR LOWER(tradeNames_string) LIKE "%pinacidil%" OR LOWER(drugSynonyms_string) LIKE "%pinacidil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1076', 'drugName': 'Pinacidil', 'tradeNames_string': 'Pindac', 'drugSynonyms_string': 'NSC-759588, Pinacidil, Pinacidil hydrate, Pinacidil monohydrate', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC9 (ENSG00000069431)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5958', 'drugName': 'Pinacidil', 'tradeNames_string': 'Pindac', 'drugSynonyms_string': 'Pinacidil', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC9 (ENSG00000069431)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.195 | Q17 | What gene does the drug Oxiglutatione target? | The drug Oxiglutatione targets the gene GSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxiglutatione%" OR LOWER(tradeNames_string) LIKE "%oxiglutatione%" OR LOWER(drugSynonyms_string) LIKE "%oxiglutatione%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4895', 'drugName': 'Oxiglutatione', 'tradeNames_string': '', 'drugSynonyms_string': 'Glutathione disulfide, Oxiglutatione', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Leukemia (EFO_0000565), Non-Small Cell Lung Carcinoma (EFO_0003060), Myelodysplastic Syndrome (EFO_0000198), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GSR (ENSG00000104687)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1281 | Q17 | What gene does the drug Vinblastine target? | The drug Vinblastine targets 15 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vinblastine%" OR LOWER(tradeNames_string) LIKE "%vinblastine%" OR LOWER(drugSynonyms_string) LIKE "%vinblastine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6261', 'drugName': 'Vinblastine Sulfate', 'tradeNames_string': 'Velban, Velbe, Vinblast,lederle, Vinblastine sulfate', 'drugSynonyms_string': '29060-LE, 29060LE, Alkaban-aq, NSC-49842, Vinblastine sulfate, Vinblastine sulphate, Vinblastini sulfas, Vincaleukoblastine sulfate, Vlb monosulfate', 'linkedDiseasesDrug_string': 'Childhood Germ Cell Tumor (MONDO_0003751), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642), Prostate Cancer (MONDO_0008315), Lymphoma (EFO_0000574), Urethra Cancer (MONDO_0004192), Testicular Neoplasm (EFO_0004281), Fungal Infectious Disease (MONDO_0002041), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Cutaneous Melanoma (EFO_0000389), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Lung Cancer (MONDO_0008903), Urinary Bladder Cancer (MONDO_0001187), Classic Hodgkin Lymphoma (MONDO_0009348), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Desmoid-Type Fibromatosis (EFO_0009907)', 'yearOfFirstApproval': 1965, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}, {'UUID': 'DrugGeneTargets_v2_4166', 'drugName': 'Vinblastine', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-47842, Velban, Vinblastine, [3H]-Vinblastine', 'linkedDiseasesDrug_string': 'Langerhans Cell Histiocytosis (EFO_1000318), Childhood Germ Cell Tumor (MONDO_0003751), Skin Cancer (MONDO_0002898), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642), Prostate Cancer (MONDO_0008315), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Testicular Neoplasm (EFO_0004281), Central Nervous System Neoplasm (EFO_1000158), Urinary Bladder Carcinoma (MONDO_0004986), Fungal Infectious Disease (MONDO_0002041), Neurofibromatosis Type 1 (MONDO_0018975), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Stricture (EFO_0006818), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Classic Hodgkin Lymphoma (MONDO_0009348), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Desmoid-Type Fibromatosis (EFO_0009907)', 'yearOfFirstApproval': 1965, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1381 | Q17 | What gene does the drug Mobocertinib target? | The drug Mobocertinib targets the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mobocertinib%" OR LOWER(tradeNames_string) LIKE "%mobocertinib%" OR LOWER(drugSynonyms_string) LIKE "%mobocertinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4962', 'drugName': 'Mobocertinib', 'tradeNames_string': '', 'drugSynonyms_string': 'AP-32788, AP32788, Mobocertinib, TAK-788, Tak-788', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1983', 'drugName': 'Mobocertinib Succinate', 'tradeNames_string': 'Exkivity', 'drugSynonyms_string': 'Mobocertinib succinate', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.677 | Q17 | What gene does the drug Selegiline Hydrochloride target? | The drug Selegiline Hydrochloride targets the gene MAOB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%selegiline hydrochloride%" OR LOWER(tradeNames_string) LIKE "%selegiline hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%selegiline hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_991', 'drugName': 'Selegiline Hydrochloride', 'tradeNames_string': 'Centrapryl 10, Centrapryl 5, Eldepryl, Ensam, Selegiline hydrochloride, Stilline 10, Stilline 5, Vivapryl, Zelapar', 'drugSynonyms_string': 'L-deprenyl, NSC-759259, Selegiline hcl, Selegiline hydrochloride', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Cannabis Dependence (EFO_0007191)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAOB (ENSG00000069535)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.795 | Q17 | What gene does the drug Linzagolix target? | The drug Linzagolix targets the gene GNRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%linzagolix%" OR LOWER(tradeNames_string) LIKE "%linzagolix%" OR LOWER(drugSynonyms_string) LIKE "%linzagolix%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_628', 'drugName': 'Linzagolix', 'tradeNames_string': '', 'drugSynonyms_string': 'KLH-2109, Klh-2109, Linzagolix, OBE-2109, OBE2109', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Liver Disease (EFO_0001421), Endometriosis (EFO_0001065), Uterine Fibroid (EFO_0000731)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1463 | Q17 | What gene does the drug Fentanyl target? | The drug Fentanyl targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fentanyl%" OR LOWER(tradeNames_string) LIKE "%fentanyl%" OR LOWER(drugSynonyms_string) LIKE "%fentanyl%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3916', 'drugName': 'Fentanyl Hydrochloride', 'tradeNames_string': 'Ionsys', 'drugSynonyms_string': 'Fentanyl hcl, Fentanyl hydrochloride', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_733', 'drugName': 'Fentanyl Citrate', 'tradeNames_string': 'Abstral, Actiq, Fentanyl, Fentanyl citrate, Fentanyl citrate preservative free, Fentora, Lazanda, Onsolis, Sublimaze, Sublimaze preservative free, Thalamonal', 'drugSynonyms_string': 'Fentanyl buccal, Fentanyl citrate, Fentanyl citrate cii, Instanyl, Kw-2246, Leptanal, MCN-JR-4263-49, R-4263', 'linkedDiseasesDrug_string': 'Shortness Of Breath (EFO_0009727), Cancer (MONDO_0004992), Dyspnea (HP_0002094), Pulpitis (EFO_1001139), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Interstitial Lung Disease (EFO_0004244), Low Back Pain (HP_0003419), Injury (EFO_0000546)', 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6302', 'drugName': 'Fentanyl', 'tradeNames_string': 'Abstral, Actiq, Breakyl, Duragesic, Duragesic-100, Duragesic-12, Duragesic-25, Duragesic-37, Duragesic-50, Duragesic-75, Durogesic, Durogesic dtrans, Effentora, Fencino, Fentalis reservoir, Fentanyl-100, Fentanyl-12, Fentanyl-25, Fentanyl-37, Fentanyl-50, Fentanyl-62, Fentanyl-75, Fentanyl-87, Fentora, Ionsys, Leptanal, Matrifen, Mezolar matrix, Mylafent, Opiodur, Oralet, Osmach, Osmanil, Pecfent, Recivit, Sublimaze, Subsys, Tilofyl, Victanyl, Yemex', 'drugSynonyms_string': 'AD 923, AD-923, Abstral-, Durogesic d-trans, EN-3267, En3267, Fendrop, Fentanest, Fentanyl, Fentanyl cii, Fentora, IDS-NF-001, Innovar, Ionsys, N02AB03, Phentanyl, R 4263, Recuvyra, Sublimase', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Liver Disease (EFO_0001421), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Migraine Disorder (MONDO_0005277), Irritable Bowel Syndrome (EFO_0000555), Injury (EFO_0000546), Hypotension (EFO_0005251), Pregnancy (EFO_0002950), Gastric Cancer (MONDO_0001056), Respiratory Insufficiency (HP_0002093), Hypospadias (EFO_0004209), Bronchospasm (HP_0025428), Breast Cancer (MONDO_0007254), Neuropathic Pain (EFO_0005762), Acute Respiratory Distress Syndrome (EFO_1000637), Scoliosis (EFO_0004273), Respiratory Depression (EFO_0009842), Interstitial Lung Disease (EFO_0004244), Morbid Obesity (EFO_0001074), Bone Fracture (EFO_0003931), Bone Metastasis (EFO_0009870), Pancreatic Carcinoma (EFO_0002618), Delirium (EFO_0009267), Subarachnoid Hemorrhage (EFO_0000713), Adenoma (EFO_0000232), Brain Injury (MONDO_0043510), Obstructive Sleep Apnea (EFO_0003918), Opioid Dependence (EFO_0005611), Shortness Of Breath (EFO_0009727), Dyspnea (HP_0002094), Chronic Kidney Disease (EFO_0003884), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Neoplasm (EFO_0000616), Diabetic Neuropathy (EFO_1000783), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Abscess (EFO_0003030), Aortic Coarctation (EFO_1001267)', 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1391', 'drugName': 'Remifentanil', 'tradeNames_string': '', 'drugSynonyms_string': 'GI 87084X, IDS-NR-005, Ramifentanyl, Remifentanil, Remifentanyl, Ultiva, Ultiva-', 'linkedDiseasesDrug_string': 'Ear Neoplasm (MONDO_0021233), Sleep Apnea (EFO_0003877), Opioid Use Disorder (EFO_0010702), Heart Disease (EFO_0003777), Premature Birth (EFO_0003917), Neoplasm (EFO_0000616), Postherpetic Neuralgia (MONDO_0041052), Stroke (EFO_0000712), Pain (EFO_0003843), Brain Neoplasm (EFO_0003833), Respiratory Depression (EFO_0009842), Obstructive Sleep Apnea (EFO_0003918), Morbid Obesity (EFO_0001074), Respiratory Insufficiency (HP_0002093), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2019', 'drugName': 'Alfentanil', 'tradeNames_string': '', 'drugSynonyms_string': 'Afentanyl, Alfentanil, Alfentanyl, IDS-NA-014, R-39209, R-39209-', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3533', 'drugName': 'Sufentanil', 'tradeNames_string': '', 'drugSynonyms_string': 'IDS-NS-001, R 30,730, R-30730, Sufentanil, Sufentanyl', 'linkedDiseasesDrug_string': 'Pulpitis (EFO_1001139), Pain (EFO_0003843), Chronic Pain (HP_0012532), Delirium (EFO_0009267), Back Pain (HP_0003418), Injury (EFO_0000546), Pregnancy (EFO_0002950)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1457 | Q17 | What gene does the drug Azaribine target? | The drug Azaribine targets the gene UMPS. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azaribine%" OR LOWER(tradeNames_string) LIKE "%azaribine%" OR LOWER(drugSynonyms_string) LIKE "%azaribine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5699', 'drugName': 'Azaribine', 'tradeNames_string': 'Triazure', 'drugSynonyms_string': 'Azaribine, CB 304, CB-304, NSC-67239', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'UMPS (ENSG00000114491)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.144 | Q17 | What gene does the drug Clopidogrel target? | The drug Clopidogrel targets the gene P2RY12. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clopidogrel%" OR LOWER(tradeNames_string) LIKE "%clopidogrel%" OR LOWER(drugSynonyms_string) LIKE "%clopidogrel%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5437', 'drugName': 'Clopidogrel Bisulfate', 'tradeNames_string': 'Clopidogrel bisulfate, Plavix', 'drugSynonyms_string': 'Clopidogrel (as bisulfate), Clopidogrel (as hydrogen sulfate), Clopidogrel bisulfate, Clopidogrel bisulphate, Clopidogrel bms, Clopidogrel hydrogen sulfate, Clopidogrel hydrogen sulphate, Clopidogrel ratiopharm, Clopidogrel sulfate, Clopidogrel teva, Clopidogrel zentiva, Clopidogrel-bgr, Clopidogrel-bms, Isocover, Pidogrel, SR 25990C, SR-25990C', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Coronary Artery Disease (EFO_0001645), Peripheral Arterial Disease (EFO_0004265), Gastrointestinal Hemorrhage (HP_0002239), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Acute Coronary Syndrome (EFO_0005672), Intermediate Coronary Syndrome (EFO_1000985), Ischemia (EFO_0000556)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'P2RY12 (ENSG00000169313)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6029', 'drugName': 'Clopidogrel', 'tradeNames_string': 'Grepid, Iscover, Plavix', 'drugSynonyms_string': 'Clopidogrel, Clopidogrel 1a-pharma, Clopidogrel acino, Clopidogrel apotex, Clopidogrel benzenesulfonate, Clopidogrel besilate, Clopidogrel besylate, Clopidogrel hexal, Clopidogrel sandoz, Clopidogrel-ratiopharm, NSC-758613, R 130964, R-130964, SR 25990, SR-25990, Zyllt', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Pneumonia (EFO_0003106), Hemorrhage (MP_0001914), Peripheral Arterial Disease (EFO_0004265), Covid-19 (MONDO_0100096), Arteriosclerosis (EFO_0009086), Pulmonary Arterial Hypertension (EFO_0001361), Peripheral Vascular Disease (EFO_0003875), St Elevation Myocardial Infarction (EFO_0008585), Systemic Lupus Erythematosus (MONDO_0007915), Pregnancy (EFO_0002950), Polycythemia Vera (EFO_0002429), Abnormality Of Cardiovascular System Morphology (HP_0030680), Atrial Fibrillation (EFO_0000275), Breast Neoplasm (EFO_0003869), Recurrent Thrombophlebitis (HP_0004419), Ischemic Stroke (HP_0002140), Angina Pectoris (EFO_0003913), Cardiovascular Disease (EFO_0000319), Acute Myocardial Infarction (EFO_0008583), Thrombotic Disease (MONDO_0000831), Acute Coronary Syndrome (EFO_0005672), Intermediate Coronary Syndrome (EFO_1000985), Brain Infarction (EFO_0004277), Thrombophilia (EFO_0009315), Asthma (MONDO_0004979), Aortic Stenosis (EFO_0000266), Viral Pneumonia (EFO_0007541), Stroke (EFO_0000712), Brain Aneurysm (EFO_0003870), Myocardial Infarction (EFO_0000612), Hiv-1 Infection (EFO_0000180), Venous Thromboembolism (EFO_0004286), Influenza (EFO_0007328), Systemic Scleroderma (EFO_0000717), Transient Ischemic Attack (EFO_0003764), Heart Disease (EFO_0003777), Head And Neck Malignant Neoplasia (EFO_0006859), Hiv Infection (EFO_0000764), Intermittent Vascular Claudication (EFO_0003876), Chronic Kidney Disease (EFO_0003884), Internal Carotid Artery Stenosis (EFO_0002615), Heart Failure (EFO_0003144), Gastrointestinal Hemorrhage (HP_0002239), Cerebral Atherosclerosis (EFO_1000860), Respiratory Failure (EFO_0009686), Vascular Disease (EFO_0004264), Major Depressive Disorder (MONDO_0002009), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914), Ischemia (EFO_0000556)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'P2RY12 (ENSG00000169313)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1188 | Q17 | What gene does the drug Interferon Alfa-2B target? | The drug Interferon Alfa-2B targets 2 genes: IFNAR1 and IFNAR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%interferon alfa-2b%" OR LOWER(tradeNames_string) LIKE "%interferon alfa-2b%" OR LOWER(drugSynonyms_string) LIKE "%interferon alfa-2b%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4596', 'drugName': 'Interferon Alfa-2B', 'tradeNames_string': 'Intron a, Intron a hsa-free, Intron-A, Viraferon', 'drugSynonyms_string': 'Interferon alfa-2b, SCH 30500, SCH-30500', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Covid-19 (MONDO_0100096), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Anogenital Venereal Wart (EFO_0007147), Breast Carcinoma In Situ (MONDO_0004658), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Hepatitis C Virus Infection (EFO_0003047), Breast Neoplasm (EFO_0003869), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Hepatitis B Virus Infection (EFO_0004197), Chronic Hepatitis B Virus Infection (EFO_0004239), Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Metastasis (EFO_0009708), Pancreatic Carcinoma (EFO_0002618), Human Papilloma Virus Infection (EFO_0001668), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Chronic Hepatitis C Virus Infection (EFO_0004220), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Cirrhosis Of Liver (EFO_0001422)", 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5976', 'drugName': 'Ropeginterferon Alfa-2B', 'tradeNames_string': 'Besremi', 'drugSynonyms_string': 'Aop2014, Besremi, P-1101, P1101, Ropeginterferon alfa-2b, Ropeginterferon alfa-2b njft, Ropeginterferon alfa-2b-njft', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Neoplasm (EFO_0000616), Chronic Hepatitis B Virus Infection (EFO_0004239), Essential Thrombocythemia (EFO_0000479), Hepatitis D Virus Infection (EFO_0007304), Chronic Hepatitis C Virus Infection (EFO_0004220), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2953', 'drugName': 'Peginterferon Alfa-2B', 'tradeNames_string': 'Peg-Intron, Pegintron', 'drugSynonyms_string': 'Peg-interferon alfa-2b, Pegifn alfa-2b, Peginterferon alfa-2b, Peginterferon-alfa-2b, Pegylated interferon alpha 2b, Sylatron', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Primary Myelofibrosis (EFO_0002430), Essential Thrombocythemia (EFO_0000479), Metastatic Melanoma (EFO_0002617), Aids (EFO_0000765), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642), Hepatitis C Virus Infection (EFO_0003047), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Chronic Hepatitis B Virus Infection (EFO_0004239), Hepatitis D Virus Infection (EFO_0007304), Cholangiocarcinoma (EFO_0005221), Metastasis (EFO_0009708), Neurofibromatosis Type 1 (MONDO_0018975), Plexiform Neurofibroma (EFO_0000658), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Chronic Hepatitis C Virus Infection (EFO_0004220), Glioma (EFO_0005543), Hiv-1 Infection (EFO_0000180), Skin Carcinoma (EFO_0009259), Craniopharyngioma (EFO_1000209), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Pilocytic Astrocytoma (MONDO_0016691), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Hiv Infection (EFO_0000764), Hepatitis (HP_0012115), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6085', 'drugName': 'Albinterferon Alfa-2B', 'tradeNames_string': 'Albuferon', 'drugSynonyms_string': 'Albinterferon alfa-2b, Interferon-alfa-2b', 'linkedDiseasesDrug_string': 'Chronic Hepatitis C Virus Infection (EFO_0004220), Chronic Hepatitis B Virus Infection (EFO_0004239), Hepatitis C Virus Infection (EFO_0003047), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.3 | Q17 | What gene does the drug Epoprostenol target? | The drug Epoprostenol targets the gene PTGIR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epoprostenol%" OR LOWER(tradeNames_string) LIKE "%epoprostenol%" OR LOWER(drugSynonyms_string) LIKE "%epoprostenol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2582', 'drugName': 'Epoprostenol', 'tradeNames_string': '', 'drugSynonyms_string': 'ACT-385781A, Epoprostenol, Flolan, PG-I2, Pgi2, Pgx, Prostacyclin, Prostaglandin i2, Prostaglandin x, U-53,217, U-53217', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Pulmonary Hypertension (MONDO_0005149), Ischemia Reperfusion Injury (EFO_0002687), Covid-19 (MONDO_0100096), Pulmonary Arterial Hypertension (EFO_0001361), Subarachnoid Hemorrhage (EFO_0000713), Brain Injury (MONDO_0043510)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGIR (ENSG00000160013)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1500', 'drugName': 'Epoprostenol Sodium', 'tradeNames_string': 'Epoprostenol sodium, Flolan, Veletri', 'drugSynonyms_string': 'Epoprostenol sodium, Epoprostenolsodium, Prostacyclin sodium salt, Sodium prostacyclin, U-53,217A, U-53217A', 'linkedDiseasesDrug_string': 'Pulmonary Arterial Hypertension (EFO_0001361)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGIR (ENSG00000160013)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.743 | Q17 | What gene does the drug Dicyclomine target? | The drug Dicyclomine targets 2 genes: CHRM1 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dicyclomine%" OR LOWER(tradeNames_string) LIKE "%dicyclomine%" OR LOWER(drugSynonyms_string) LIKE "%dicyclomine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2581', 'drugName': 'Dicyclomine', 'tradeNames_string': '', 'drugSynonyms_string': 'Bentyl, Dicyclomine, Dicycloverine, Dicymine, Kolantyl', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555), Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2580', 'drugName': 'Dicyclomine', 'tradeNames_string': '', 'drugSynonyms_string': 'Bentyl, Dicyclomine, Dicycloverine, Dicymine, Kolantyl', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555), Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2300', 'drugName': 'Dicyclomine Hydrochloride', 'tradeNames_string': 'Bentyl, Bentyl preservative free, Dicyclomine Hydrochloride (Preservative-Free), Dicyclomine hydrochloride, Dicyclomine hydrochloride (preservative free), Merbentyl, Merbentyl 20', 'drugSynonyms_string': 'Bentylol, Dicyclomine hcl, Dicyclomine hydrochloride, Dicycloverine hydrochloride, Kolantyl hydrochloride, NSC-404381, Wyovin', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2299', 'drugName': 'Dicyclomine Hydrochloride', 'tradeNames_string': 'Bentyl, Bentyl preservative free, Dicyclomine Hydrochloride (Preservative-Free), Dicyclomine hydrochloride, Dicyclomine hydrochloride (preservative free), Merbentyl, Merbentyl 20', 'drugSynonyms_string': 'Bentylol, Dicyclomine hcl, Dicyclomine hydrochloride, Dicycloverine hydrochloride, Kolantyl hydrochloride, NSC-404381, Wyovin', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1871 | Q17 | What gene does the drug Clenoliximab target? | The drug Clenoliximab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clenoliximab%" OR LOWER(tradeNames_string) LIKE "%clenoliximab%" OR LOWER(drugSynonyms_string) LIKE "%clenoliximab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2758', 'drugName': 'Clenoliximab', 'tradeNames_string': '', 'drugSynonyms_string': 'CE9.GAMMA.4PE, CE9?4PE, Clenoliximab, IDEC-151, IDEC151', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD4 (ENSG00000010610)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1516 | Q17 | What gene does the drug Rosiglitazone target? | The drug Rosiglitazone targets the gene PPARG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rosiglitazone%" OR LOWER(tradeNames_string) LIKE "%rosiglitazone%" OR LOWER(drugSynonyms_string) LIKE "%rosiglitazone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4628', 'drugName': 'Rosiglitazone Maleate', 'tradeNames_string': 'Avandia, Rosiglitazone maleate', 'drugSynonyms_string': 'Avandia, BRL-49653, BRL-49653-C, BRL-49653C, NSC-717764, Rosiglitazone maleate, Rosiglitzazone maleate', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Central Nervous System Neoplasm (EFO_1000158), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Head And Neck Malignant Neoplasia (EFO_0006859), Oral Leukoplakia (HP_0002745), Hiv Infection (EFO_0000764), Congestive Heart Failure (EFO_0000373), Insulin Resistance (EFO_0002614), Non-Alcoholic Steatohepatitis (EFO_1001249), Sarcoma (EFO_0000691), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)", 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6144', 'drugName': 'Rosiglitazone', 'tradeNames_string': 'Avandia', 'drugSynonyms_string': 'Avandamet, Avandaryl, Avandia, BRL-49653, Gaudil, NSC-758698, Rezult, Rosiglitazone, Rosiglizole, Rosvel, TDZ-01', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Cancer (MONDO_0004992), Sezary'S Disease (EFO_1000785), Erectile Dysfunction (EFO_0004234), Coronary Artery Disease (EFO_0001645), Alzheimer Disease (MONDO_0004975), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Plasmodium Falciparum Malaria (EFO_0007444), Ulcerative Colitis (EFO_0000729), Focal Segmental Glomerulosclerosis (EFO_0004236), Metabolic Disease (EFO_0000589), Malaria (EFO_0001068), Prostate Adenocarcinoma (EFO_0000673), Congestive Heart Failure (EFO_0000373), Oral Leukoplakia (HP_0002745), Breast Cancer (MONDO_0007254), Hypertension (EFO_0000537), Non-Alcoholic Steatohepatitis (EFO_1001249), Multiple Organ Failure (EFO_1001373), Glucose Intolerance (HP_0001952), Endometriosis (EFO_0001065), Mycosis Fungoides (EFO_1001051), Disorder Of Lipid Metabolism (Orphanet_309005), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Central Nervous System Neoplasm (EFO_1000158), Asthma (MONDO_0004979), Insulin Resistance (EFO_0002614), Anemia (Phenotype) (EFO_0004272), Abnormal Glucose Tolerance (EFO_0002546), Hypercholesterolemia (HP_0003124), Rheumatoid Arthritis (EFO_0000685), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Head And Neck Malignant Neoplasia (EFO_0006859), Hiv Infection (EFO_0000764), Cognitive Impairment (HP_0100543), Neoplasm (EFO_0000616), Diabetic Neuropathy (EFO_1000783), Sarcoma (EFO_0000691), Metabolic Syndrome (EFO_0000195), Prediabetes Syndrome (EFO_1001121), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)", 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.343 | Q17 | What gene does the drug Verinurad target? | The drug Verinurad is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SLC22A12. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%verinurad%" OR LOWER(tradeNames_string) LIKE "%verinurad%" OR LOWER(drugSynonyms_string) LIKE "%verinurad%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4625', 'drugName': 'Verinurad', 'tradeNames_string': '', 'drugSynonyms_string': 'RDEA-3170, RDEA3170, Verinurad', 'linkedDiseasesDrug_string': 'Gout (EFO_0004274), Hyperuricemia (EFO_0009104), Chronic Kidney Disease (EFO_0003884), Heart Failure (EFO_0003144)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC22A12 (ENSG00000197891)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.626 | Q17 | What gene does the drug Tedalinab target? | The drug Tedalinab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CNR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tedalinab%" OR LOWER(tradeNames_string) LIKE "%tedalinab%" OR LOWER(drugSynonyms_string) LIKE "%tedalinab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4928', 'drugName': 'Tedalinab', 'tradeNames_string': '', 'drugSynonyms_string': 'GRC10693, Grc-10693, Tedalinab', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CNR2 (ENSG00000188822)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.484 | Q17 | What gene does the drug Fesoterodine target? | The drug Fesoterodine targets 2 genes: CHRM2 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fesoterodine%" OR LOWER(tradeNames_string) LIKE "%fesoterodine%" OR LOWER(drugSynonyms_string) LIKE "%fesoterodine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1582', 'drugName': 'Fesoterodine', 'tradeNames_string': '', 'drugSynonyms_string': 'Fesoterodine', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Polyuria (HP_0000103), Overactive Bladder (EFO_1000781), Autonomic Dysreflexia (EFO_1001762), Neurogenic Bladder (HP_0000011), Urinary Incontinence (HP_0000020)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1581', 'drugName': 'Fesoterodine', 'tradeNames_string': '', 'drugSynonyms_string': 'Fesoterodine', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Polyuria (HP_0000103), Overactive Bladder (EFO_1000781), Autonomic Dysreflexia (EFO_1001762), Neurogenic Bladder (HP_0000011), Urinary Incontinence (HP_0000020)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3363', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_string': 'Fesoterodine fumarate, Toviaz', 'drugSynonyms_string': 'Fesoterodine fumarate, SPM 8272, SPM 907, SPM-8272, SPM-907', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Urinary Incontinence (HP_0000020), Overactive Bladder (EFO_1000781)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3362', 'drugName': 'Fesoterodine Fumarate', 'tradeNames_string': 'Fesoterodine fumarate, Toviaz', 'drugSynonyms_string': 'Fesoterodine fumarate, SPM 8272, SPM 907, SPM-8272, SPM-907', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Urinary Incontinence (HP_0000020), Overactive Bladder (EFO_1000781)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.532 | Q17 | What gene does the drug Bay1067197 target? | The drug Bay1067197 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ADORA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bay1067197%" OR LOWER(tradeNames_string) LIKE "%bay1067197%" OR LOWER(drugSynonyms_string) LIKE "%bay1067197%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6009', 'drugName': 'Bay1067197', 'tradeNames_string': '', 'drugSynonyms_string': 'BAY-10-67197, BAY-1067197, BAY10-67197, BAY1067197, Bay1067197, Neladenoson bialanate, Neladenoson dalanate', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.268 | Q17 | What gene does the drug Acalabrutinib target? | The drug Acalabrutinib targets the gene BTK. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acalabrutinib%" OR LOWER(tradeNames_string) LIKE "%acalabrutinib%" OR LOWER(drugSynonyms_string) LIKE "%acalabrutinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_593', 'drugName': 'Acalabrutinib', 'tradeNames_string': 'Calquence', 'drugSynonyms_string': 'ACP-196, Acalabrutinib, Acp-196', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Covid-19 (MONDO_0100096), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Infectious Disease (EFO_0005741), Food Allergy (EFO_1001890), Ovarian Cancer (MONDO_0008170), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Waldenstrom Macroglobulinemia (EFO_0009441), Rheumatoid Arthritis (EFO_0000685), Prolymphocytic Leukemia (MONDO_0001023), Follicular Lymphoma (MONDO_0018906), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BTK (ENSG00000010671)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6297', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_string': 'Calquence', 'drugSynonyms_string': 'Acalabrutinib maleate, Acalabrutinib maleate anhydrous, Calquence maleate', 'linkedDiseasesDrug_string': 'Chronic Lymphocytic Leukemia (EFO_0000095), Mantle Cell Lymphoma (EFO_1001469)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BTK (ENSG00000010671)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1390 | Q17 | What gene does the drug Tapentadol target? | The drug Tapentadol targets 2 genes: SLC6A2 and OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tapentadol%" OR LOWER(tradeNames_string) LIKE "%tapentadol%" OR LOWER(drugSynonyms_string) LIKE "%tapentadol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6373', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_string': 'Nucynta, Nucynta er, Palexia', 'drugSynonyms_string': 'BN-200 HYDROCHLORIDE, CG-5503 HYDROCHLORIDE, CG5503 HYDROCHLORIDE, Tapentadol hcl, Tapentadol hydrochloride', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Neuropathic Pain (EFO_0005762)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6372', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_string': 'Nucynta, Nucynta er, Palexia', 'drugSynonyms_string': 'BN-200 HYDROCHLORIDE, CG-5503 HYDROCHLORIDE, CG5503 HYDROCHLORIDE, Tapentadol hcl, Tapentadol hydrochloride', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Neuropathic Pain (EFO_0005762)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4013', 'drugName': 'Tapentadol', 'tradeNames_string': '', 'drugSynonyms_string': 'BN 200 (BASE), BN-200, CG-5503, CG5503, CG5503 (BASE), CG5503 IR, NSC-759619, Tapentadol', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178), Diabetic Neuropathy (EFO_1000783), Neoplasm (EFO_0000616), Diabetic Polyneuropathy (MONDO_0001583), Osteoarthritis, Hip (EFO_1000786), Pain (EFO_0003843), Chronic Pain (HP_0012532), Osteoarthritis, Knee (EFO_0004616), Neuropathic Pain (EFO_0005762), Back Pain (HP_0003418), Joint Disease (EFO_1000999), Hallux Valgus (HP_0001822), Low Back Pain (HP_0003419)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4012', 'drugName': 'Tapentadol', 'tradeNames_string': '', 'drugSynonyms_string': 'BN 200 (BASE), BN-200, CG-5503, CG5503, CG5503 (BASE), CG5503 IR, NSC-759619, Tapentadol', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178), Diabetic Neuropathy (EFO_1000783), Neoplasm (EFO_0000616), Diabetic Polyneuropathy (MONDO_0001583), Osteoarthritis, Hip (EFO_1000786), Pain (EFO_0003843), Chronic Pain (HP_0012532), Osteoarthritis, Knee (EFO_0004616), Neuropathic Pain (EFO_0005762), Back Pain (HP_0003418), Joint Disease (EFO_1000999), Hallux Valgus (HP_0001822), Low Back Pain (HP_0003419)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.681 | Q17 | What gene does the drug Interferon Beta-1A target? | The drug Interferon Beta-1A targets 2 genes: IFNAR1 and IFNAR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%interferon beta-1a%" OR LOWER(tradeNames_string) LIKE "%interferon beta-1a%" OR LOWER(drugSynonyms_string) LIKE "%interferon beta-1a%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_635', 'drugName': 'Interferon Beta-1A', 'tradeNames_string': 'Avonex, Neoferon, Rebif', 'drugSynonyms_string': 'Interferon beta-1a, SNG-001, SNG001, Sng001', 'linkedDiseasesDrug_string': "Alzheimer Disease (MONDO_0004975), Asthma (MONDO_0004979), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (EFO_1000868), Crohn'S Disease (EFO_0000384), Neoplasm (EFO_0000616), Pneumonia (EFO_0003106), Multiple Sclerosis (MONDO_0005301), Stroke (EFO_0000712), Covid-19 (MONDO_0100096), Chronic Obstructive Pulmonary Disease (EFO_0000341), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Multiple Organ Failure (EFO_1001373), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Influenza (EFO_0007328), Ulcerative Colitis (EFO_0000729), Hepatitis C Virus Infection (EFO_0003047)", 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4925', 'drugName': 'Peginterferon Beta-1A', 'tradeNames_string': 'Biib017, Plegridy', 'drugSynonyms_string': 'BIIB-017, BIIB017, Peginterferon beta, Peginterferon beta-1a', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Renal Insufficiency (HP_0000083), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.